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ABSTRACT 
 
 Proteins and glycoproteins have the potential to improve health when used as 
therapeutic products for prevention or treatment of disease, but methods are needed for 
solving some remaining challenges to production, optimization, and analysis. In this 
dissertation, novel glycosylation engineering strategies are used to solve challenges in 
conventional protein production and are used to improve therapeutic protein stability by 
blocking asparagine deamidation, a ubiquitous cause of protein degradation. Glycan 
structures on therapeutic glycoproteins must be optimized to avoid negative impacts on 
pharmacological properties. Methods to optimize glycans are described within, using 
novel, extracellular glycan trimming reactions performed with glycosidases that can be 
implemented without harm to protein activity or stability. Finally, analysis of proteins with 
mass spectrometric peptide mass fingerprinting techniques can be complex, so mass 
defect filters used for data analysis were improved by determining the correct filter size, 
using experimental human protein data. 
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CHAPTER 1 INTRODUCTION 
 
 Proteins and glycoproteins are used as the active therapeutic agent for treating 
or preventing many different diseases, and despite advances in therapeutic product 
development, challenges remain to be addressed. Areas in the field that will benefit 
from demonstration of new methods include protein production, pharmacological 
property optimization, and protein analysis. The contiguous pages encompass an 
introduction to protein and glycoprotein therapeutic composition, describe some 
examples of Food and Drug Administration approved therapeutic proteins, and 
introduce recombinant technology and lectin affinity chromatography techniques used to 
produce and purify the products. Then, analytical methods that are used to determine 
the composition and structure of therapeutic proteins are discussed. Finally, subsequent 
chapters present work that is intended for making further improvements to protein and 
glycoprotein therapeutic products. 
 
1.1 PROTEIN AND GLYCOPROTEIN THERAPEUTICS 
 
1.1.1 Overview of therapeutic proteins, glycoproteins, and glycosylation   
 Proteins may be developed into a therapeutic product, after the specific function 
or effect of the protein is identified. Proteins consist of an amino acid sequence that is 
encoded by DNA, which is used to express the protein using recombinant technology,1,2 
discussed below. The protein is produced and purified in soluble, folded, and active 
form, and must be optimized with regard to a range of pharmacological properties.1 To 
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be a high quality therapeutic product, the recombinant protein must, for example, 
contain the correct post-translational modifications (PTMs), such as the glycosylation 
structures that are known to provide optimal therapeutic effects.3-5  
 N-linked glycans are appended to a protein when the amino acid consensus 
sequence (N-X-S/T) is present in the protein primary structure, where X is any amino 
acid other than proline.3,4 The type of N-linked glycan that will be present at a particular 
glycosylation site is determined by the cofactors, glycosyltransferases, and 
glycosidases located in the rough endoplasmic reticulum (RER) and Golgi bodies that 
comprise the cellular expression system.3-5 The glycan composition is dependent upon 
cellular environment is very different from the direct genetic encoding that occurs for the 
amino acid sequence.3-5 While protein synthesis is template driven, glycosylation is not.  
Instead, glycosylation on a protein depends on the activity of the glycosyltransferases 
and glycosidases (collectively the glycoenzymes) and availability of cofactors; these are 
a direct consequence of the local environment within the cell, which can vary 
significantly.8 
 Therapeutic glycoproteins are produced with the goal of including glycan 
moieties that are similar to naturally occurring human glycans.4-7 The two most common 
forms of glycosylation in human proteins, N- and O- linked, both consist of the same 
individual carbohydrate building blocks, but are attached to the protein sequence either 
through the side chain of an asparagine residue (N-linked glycans), or to the hydroxyl 
group of serine or threonine (O-linked glycans), respectively.3,4 N-linked glycans have 
been studied extensively, and are known to exist as one of three main types as 
described in Figure 1.  
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Figure 1. Three main classes of N-linked glycans: high mannose, hybrid, and complex. All three share 
the same pentasaccharide core structure, then terminate with different carbohydrate residues. 
 
 The N-linked glycan types, high mannose, hybrid, and complex, all share the 
same pentasaccharide core, as shown in the figure. The classification depicted in 
Figure 1 is determined by the identity of the terminal carbohydrate residues, which are 
acquired during further enzymatic processing in the Golgi body of a cell.4,7 Terminal 
residues generally consist of only mannose residues in high mannose type, galactose or 
sialic acids in complex type. In a hybrid type structure, at least one branch terminates in 
high mannose and one branch resembles complex type glycans.4 Figure 1 depicts 
triantennary and tetrantennary branching; biantennary glycans have only two branches 
(not shown).  
 Individual carbohydrate residues are linked together in various linkage types, α or 
β, and the linkages are referred to by the carbon number assigned around the 
carbohydrate ring structure.8 In Figure 2, the top example shows two carbohydrate 
residues linked with a β(1,4) bond, and the bottom shows an α(1,2) linkage. One glycan 
residue can also be attached to another at more than one position, and with more than 
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one linkage type.4,5,8 For example, sialic acid residues are often linked to galactose in 
the following configurations: α(2,3), α(2,6), or α(2,8). Thus, a high degree of 
heterogeneity may exist within the N-linked glycans located on a particular protein, 
including major glycoform structures, variable linkages, and individual structural 
isoforms.4,6,9 
 
 
Figure 2. Carbohydrate linkage configurations. The top example shows two carbohydrate residues linked 
together with a β(1,4) linkage and the bottom sugars are linked with an α(1,2) linkage. 
 
 N-linked glycan variation can be problematic, because glycan composition affects 
a wide range of pharmacological properties, such as circulation half life, 
immunogenicity, receptor binding, thermal stability, folding, charge, and product 
potency.5,7-8 These observed effects have shown that glycosylation of therapeutic 
glycoproteins must be in the correct location, and of the correct type, for the 
production of an effective and safe therapeutic product.5,8-12 The glycan post-
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translational modifications are acquired during protein production within a chosen host 
cell, and are dependant upon host cell choice, which is discussed in section 1.2.1. 
Methods to optimize glycan composition are presented in Chapters 3 and 4. 
 
1.1.2 Therapeutic protein and glycoprotein examples 
 The earliest use of proteins as therapeutics involves the purification of proteins 
from harvested tissues and organs. For example, the first use of the protein hormone, 
insulin, was demonstrated using purified insulin from dog pancreas, and the purified 
pancreatic insulin became available all over the Western world by the 1920’s for the 
treatment of diabetes.13 Just a few decades later, isolation of human growth hormone 
from human cadaver pituitary glands was performed for the treatment of growth 
hormone deficiency.14,15 Today, therapeutic protein production is performed using 
recombinant DNA technology, which is discussed below in section 1.2.1. Human growth 
hormone, and erythropoietin, another protein therapeutic produced by recombinant DNA 
technology, are the key proteins studied in this dissertation, so more detail is included 
about these proteins. 
 Human growth hormone (hGH) is an endogenous 22 kDa protein that is critical to 
proper growth and metabolism.16 The hGH protein is nonglycosylated in the most 
abundant form found in the pancreas, even though other tissues, such as the placenta, 
have been found to have glycosylated hGH.17 For the children and adults who suffer 
from hGH deficiencies, the recombinantly expressed hGH (rhGH) has become an 
important therapeutic.18-20 Growth hormone is discussed further in Chapters 2 and 5. 
Both insulin and growth hormone proteins do not need glycosylation to have the 
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intended therapeutic effect in the body, and this lack of required glycosylation allows for 
production in protein expression hosts such as bacteria.21 Unfortunately, therapeutic 
glycoproteins do not function without the proper glycosylation moieties, as is the case 
for erythropoietin, and other expression host cells are required. 
 Recombinant, human erythropoietin (rhEPO) is a glycoprotein therapeutic that 
was developed after the endogenous glycoprotein hormone erythropoietin was 
determined to be required for red blood cell production. Endogenous EPO is produced 
in the kidney and circulates in serum to the bone marrow, where it differentiates 
erythrocyte progenitor cells for the production of red blood cells.22 EPO naturally 
possesses three sialylated, complex type N-linked glycans, which are essential to 
erythropoietin’s in vivo activity.23-26 The complex type N-linked glycans of EPO have 
interesting effects on receptor binding. The receptor was determined to have an 
increased binding affinity constant for EPO after removal of the terminal sialic acid 
carbohydrate residues from the N-linked glycans.26-28 Without the sialic acids, however, 
the exposed galactose residues are bound by the liver’s galactose binding proteins, and 
EPO is cleared from circulation quickly thus non-sialylated EPO has no appreciable in 
vivo activity.23-29 Therefore, the requirement for sialylated, complex type N-linked 
glycans must be met to produce an effective glycoprotein therapeutic, and can be 
accomplished by carefully choosing the protein expression host. Host selection is 
discussed below in section 1.2.2. New methods to further optimize the N-linked glycans 
of erythropoietin are described in Chapter 4.  
 7 
1.2 RECOMBINANT PROTEIN AND GLYCOPROTEIN PRODUCTION FOR 
THERAPEUTIC USE 
 Therapeutic protein production was first accomplished by extracting and purifying 
protein hormones from tissue, such as the early use of human growth hormone and 
insulin.13-15 Production of protein and glycoprotein therapeutics is now achieved through 
the use of recombinant DNA technology. 
 
1.2.1 Protein expression using recombinant technology 
 To produce, or express, a protein using recombinant DNA, a series of steps are 
required. See Figure 3 below.  
 
 
 
Figure 3. Protein expression work-flow diagram. Recombinant DNA technology is used to express 
proteins for therapeutic use. 
 
 The first step in protein production is to obtain the DNA for the protein of interest. 
A DNA sequence is composed of the four nucleotide bases, G, C, A, and T, covalently 
bound by phosphodiester bonds, arranged into groups of three bases, called codons. 
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These codons encode for individual amino acids; and the codons are arranged in the 
order necessary to generate the amino acid sequence of the desired protein.2,30-31 The 
DNA sequence that encodes the protein, called a gene, is combined with a larger piece 
of DNA, that will act as a vector to introduce the protein gene into the chosen 
expression host,2 is shown in Figure 3. The combined DNA is the “recombinant” DNA.2 
Recombinant DNA used in protein expression is usually double stranded and circular in 
shape and called a “plasmid”. It is not a part of the host cell genetic material.30-31  
 The next step, as shown in Figure 3 is to use the vector plasmid, containing the 
gene for the target protein, to transform Escherichia coli (E.coli). The E. coli  replicate 
the plasmid to produce large amounts of the recombinant DNA, provided the plasmid 
contains the necessary DNA sequences (such as promoter regions) that act as signals 
to the E. coli, to produce the product.2,30-31 Finally, the E. coli can be lysed to purify the 
DNA, and the DNA can be introduced into the chosen protein expression host cell.2,30-31 
The host transcribes the protein DNA into mRNA, and then the mRNA is translated into 
the protein of interest.2,30-31 The choice of expression host affects glycosylation, and this 
topic is discussed vida infra.5,8-12 
 E. coli and baculovirus-directed insect cell lines have been used extensively as 
protein expression hosts,31-32 but most of the proteins are expressed in aggregate form, 
and they must be dissociated using a series of trial and error experiments that are 
designed to extract, solubilize, and refold the protein.32-35 In addition, these expression 
hosts do not provide the type of glycosylation that is required for therapeutic 
glycoproteins such as erythropoietin that require sialylated, complex type N-linked 
glycans for activity.23-29,36 Thus, E. coli and insect cell lines are generally useful for non-
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glycosylated protein production only. See Table 1 for a partial list of host cell lines that 
are used in protein production.  
 
Table 1. Protein expression host cell options.21,36-41  
Host  Examples 
Bacteria  Escherichia coli 
Insect  Drosophila melanogaster 
Yeast  Saccharomyces cerevisiae 
Schizosaccharomyces pombe 
Pichia pastoris 
Plant  Nicotiana benthamiana 
Mammal  T293-K (human) 
 Baby Hamster Kidney (BHK) 
 NS0 (mouse) 
 Chinese Hamster Ovary (CHO) 
 
All of the protein expression host cell lines in Table 1 have been tested for 
therapeutic protein or glycoprotein production, with varying degrees of success. 
Attempts at producing human-like glycosylation patterns for antibodies and other 
therapeutic glycoproteins using plant cells as an expression host have produced glycan 
moieties that still contain some level of sugars that are specific to plant cells, such as 
the β(1,2)-xlyose and α(1,3)-fucose.37 These sugar residues are immunogenic to 
humans.6,37,40 Therapeutic proteins produced using E. coli must also be carefully 
evaluated for dangerous endotoxins and high levels of acetate.42-43 Yeast strains are 
naturally capable of producing proteins with only high mannose type N-linked glycans.44-
46
 Even after extensive genetic alterations to yeast strains such as Pichia pastoris, the 
 10 
glycans contain only biantennary complex type that still lack higher degrees of 
branching observed in many human glycan structures.46 For these reasons, most 
therapeutic glycoproteins are produced in mammalian cell lines, such as Chinese 
hamster ovary (CHO) or baby hamster kidney (BHK) cells.39,40,47,48 
Even among available mammalian host cell lines such as CHO or BHK, 
considerable variation can be found in the PTMs for glycoprotein therapeutics. It is 
important to reiterate that the N-linked glycans of a protein cannot be directly controlled 
in a manner similar to the primary amino acid sequence of the protein, so optimization 
of cell culture conditions, such as choosing a desirable cell line and media formulation, 
to promote the desired glycosylation pattern, is an important focus of research in the 
therapeutic product industry.5,8-12,36-41,47-49  
One example of a case where glycan optimization is important is in 
manufacturing erythropoietin. Erythropoietin requires sialylated, complex type N-linked 
glycans to produce any therapeutic effect, but care must be taken in optimizing the 
sialylation on the protein because some forms of sialic acid can create potentially 
dangerous immune responses. N-glycolylneuraminic acid (Neu5Gc), a derivative of 
sialic acid, can be added to the N-linked glycan, and can produce an immunogenic 
response in humans.49 Figure 4 provides the chemical structures of two sialic acids, 
which are structurally very similar and differ only by a single hydroxyl group, indicated in 
a red circle. While the structural difference is small, these two compounds are clinically 
distinct, where Neu5Gc can induce an adverse response, but Neu5Ac does not.  
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Figure 4. Chemical structure of the main sialic acid, N-Acetylneuraminic Acid (Neu5Ac), and the 
structurally similar, but immunogenic, derivative, N-Glycolylneuraminic Acid (Neu5Gc). 
 
The Neu5Gc derivative is prevalent in mouse cell lines like NS0, accounting for, 
up to 50% of sialic acid species on N-linked glycans of recombinant proteins.41,47 CHO 
cell expressed glycoproteins contain significantly less Neu5Gc, estimated to be 7-15% 
of sialic acid content in some studies, depending on the cell culture conditions.47 At this 
time, 70% of approved glycoprotein therapeutic products are expressed in a CHO cell 
line due to reasons such as glycan composition,48 making expression host cell line an 
important part of therapeutic production. While CHO cells diminish the incorporation of 
Neu5Gc into erythropoietin, they do not completely suppress its presence. Therefore, 
better strategies are needed to avoid this residue, in order to maximize the safety and 
potential for long-term use of this drug. A novel strategy for removing sugar residues 
that prove to be problematic to therapeutic glycoproteins is discussed in Chapters 3 and 
4. 
After a nonglycosylated therapeutic protein is expressed, the protein must then 
be purified. A wide range of currently employed affinity tags used for protein purification 
are available, but each type of tag can be disadvantageous to protein structure or 
function, depending on the application.50
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purification platform is described in Chapter 2, for use with nonglycosylated proteins, 
which account for approximately 50% of human proteins.51 The other 50% of human 
proteins are known to be glycosylated, and the glycans can serve as a means for 
purification, using lectin affinity. Glycoprotein purification with lectin affinity is discussed 
in section 1.2.2. 
 
1.2.2 Purification using lectin affinity  
 A lectin is a protein that binds to carbohydrates.52-54 In nature, lectins bind to 
sugar residues on the surface of cells, and lectins are directly involved in the processes 
that some pathogens, such as influenza and tuberculosis, use to invade and infect 
hosts.52-54 The exploitation of the natural affinity of lectins has allowed for lectins to be 
used in many applications, from fabrication of protein thin films to glycoprotein 
purification.55,56 Erythropoietin and other glycoprotein therapeutics are often purified 
using lectin affinity.56  
 Lectins can be bound to a support resin and loaded into a cartridge or column, 
then used as part of a purification strategy using methodology similar to other affinity 
chromatography techniques.56-58 Briefly, the glycoprotein of interest is concentrated, 
mixed with a loading buffer, and applied to the column. The presence of carbohydrates 
that are recognized and bound by the lectin allow for the glycoprotein of interest to be 
retained, while other species are rinsed away. The glycoprotein is then eluted, often 
through displacement. For example, a solution containing a high concentration of a 
carbohydrate, for which the lectin will have greater affinity for than the glycan moiety of 
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the glycoprotein, is introduced so that bound glycoproteins are eluted due to 
displacement by the elution buffer’s carbohydrate.57-58 
 The physical basis for a lectin to have affinity for a glycan is primarily through 
hydrogen bonding, where the negatively charged amino acids (D and E) of the lectin 
form hydrogen bonds with the hydroxyl groups of sugar residues. Alternatively, 
hydrogen bonds can form between the amide groups of amino acids N or Q, of the 
lectin, and the sugar hydroxyl groups.59 Lectins with affinity for charged carbohydrate 
residues, such as sialic acids, also rely primarily on hydrogen bonding, where the 
uncharged, polar amino acids can have affinity for the negatively charged sialic acids.59 
Lectins that have been identified as having specificity for sialic acids and other complex 
type N-linked glycan terminal residues are displayed in Figure 5 below.  
 
 
Figure 5. Lectins with affinity for complex type N-linked glycans.52,59-61 
 The plant lectins described in the first column in Figure 5 can be useful in 
therapeutic glycoprotein purification strategies,56-59 since complex type N-linked glycans 
are a necessary component of many therapeutic glycoproteins. These particular plant 
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lectins are commercially available. Use of lectin affinity chromatography is 
demonstrated in Chapters 2, 4, and 5. After therapeutic proteins are purified, they need 
to be characterized and studied using many different analytical techniques. Mass 
spectrometry and circular dichroism spectroscopy are two such techniques, and are 
discussed below in section 1.2.3. 
 
1.2.3 Analytical chemistry in protein and glycoprotein analysis  
 Potential protein and glycoprotein therapeutic products must be well 
characterized with respect to structure and function long before they can be developed 
into a viable treatment product. Mass spectrometry (MS) is an analytical method that is 
capable of identifying the composition of a protein and its glycans with a high degree of 
confidence. Techniques for protein analysis using MS are discussed in section 1.2.3.1. 
In addition to obtaining molecular composition information, which is afforded by mass 
spectrometry, the structure of a protein must be monitored, as structure and function are 
closely linked. A low-resolution, time sensitive spectroscopic technique such as circular 
dichroism (CD) is very useful in analyzing a protein for changes in structural 
characteristics, for monitoring the protein for changes to structure throughout an 
optimization process, and even for assessing major difference in thermal stability 
between two protein samples. CD is discussed below in section 1.2.3.2. 
 
1.2.3.1 Mass spectrometry 
Mass spectrometric techniques for protein and glycoprotein analysis rely on 
instrumentation that possesses three distinct parts. See Figure 6.  
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Figure 6. Mass spectrometers consist of an ionization source, mass analyzer, and a detector 
 
 For mass spectrometric analysis to occur, the analyte of interest must become a 
gas phase ion in the ionization source, and can possess a positive or negative 
charge.62-65 The two most common ionization methods used for protein analysis are 
electrospray ionization (ESI) and matrix assisted laser desorption ionization (MALDI).64 
Both of these ionization methods are considered non-destructive, or “soft”, because 
they do not produce fragments of the analyte during the ionization process.64  
 After the ions are formed, they are sent to the mass analyzer, where they are 
separated. The transport and separation is performed under vacuum, and this section of 
the instrument is where intentional fragmentation of the sample ions may be 
accomplished.62-65 Fragmentation can be achieved using collision induced dissociation 
(CID). In this case, an ion is isolated and then fragmented via collisions with atoms of an 
inert gas, such as helium or argon.62-65 These techniques are very valuable because the 
fragmentation patterns that are generated can provide significant information regarding 
the analyte’s composition. This method is particularly useful for confirming the 
composition of the glycan structures on glycopeptides.66-70 CID is used in Chapter 4 to 
elucidate glycan composition of a therapeutic glycoprotein. The observed fragmentation 
can be used to confirm or support the composition assignments made based on the 
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data in a full mass spectrum, where the masses of the intact analytes can be measured 
with a high degree of accuracy. 
 In the detector section of the instrument, the ions, which have been previously 
separated by their mass to charge ratios, are counted. The resulting ion signal is 
recorded, and the information is used to generate a spectrum of peaks that describe the 
ions present, in terms of their ratio of mass to charge (m/z).65  
 The type of information that is obtainable from mass spectrometric analyses, 
such as glycan mass, peptide composition, or glycosylation site location and glycan 
composition, are dependent upon the procedures used to prepare the sample. 
Strategies used to prepare proteins and glycoproteins for mass spectrometric analysis 
are illustrated in Figure 7. 
 To choose the best preparative strategy prior to MS analysis, one must first 
identify the type of information that is desired. To determine the identity of N-glycans of 
a glycoprotein, the glycans could be enzymatically released from the protein using an 
endoglycosidase such as Peptide-N-glycosidase F (PNGase F), and then analyzed 
using mass spectrometry.71-73 When only a few glycans are present on a small 
glycoprotein, the whole glycoprotein can be analyzed intact. This approach is used to 
monitor glycan modification reactions in Chapter 3. 
 For larger proteins, or proteins with multiple glycosylation sites, intact analysis is 
often not a viable approach for obtaining information about the glycosylation. In these 
cases, another approach is often used for compositional analysis. This approach (often 
called “glycopeptide analysis”) relies on proteolytic digestion, which cleaves the protein 
but leaves the glycans still attached to the peptides. This sample preparation step 
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results in a mixture of peptides and glycopeptides.66-70 While the resulting mixture can 
be quite complex to analyze, this strategy provides information that other approaches 
cannot: specifically information about which glycans are attached to which particular 
glycosylation sites is obtained. This technique, which produces “glycosylation site 
specific” information, can even be used to identify multiple glycoforms attached to the 
protein at a single site.66-70 Glycopeptide analysis may prove especially beneficial in the 
therapeutic development work-flow, since this technique provides value-added 
information, compared to other methods of glycan or peptide analysis. 
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Figure 7. Strategies for protein and glycoprotein analysis using mass spectrometry.  
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 After the MS experiment has been completed, data analysis begins, which is 
sometimes extensive, complicated, and time consuming. Peptide data analysis is often 
simplified by filtering the data to remove peaks that are unlikely to be identified as a 
peptide, based on residual mass, or mass defect.71,74 Then the data is submitted to an 
analysis program such as Mascot.75,76 Currently employed data filters used in peptide 
mass fingerprinting experiments are based on values that were calculated using a set of 
theoretical peptides.75,76 In Chapter 6, calculations from human protein data sets are 
presented to improve selectivity of the mass defect data filters. Mass spectrometric 
analysis of glycoproteins can also be aided during data analysis, using an analysis tool 
such as GlycoPepDB and GlycoPepID.67-68 
 In addition to mass spectrometric analysis, a structural analysis method is 
needed for use when developing therapeutic proteins and glycoproteins. Circular 
dichroism is one commonly used method, and it is discussed below.  
 
1.2.3.2 Circular dichroism 
 Circular dichroism (CD) is a spectroscopic technique that can be used for low 
resolution assessment of protein or glycoprotein structure. CD cannot discern protein 
structure to the near Ångström level, as can techniques like nuclear magnetic 
resonance (NMR) and X-ray crystallography, but some agreement has been shown 
between NMR and CD data results.77,78 Instead of high resolution structural data, CD is 
used for its time sensitivity, where data may take 10 minutes to collect and analyze, 
while protein NMR and crystallography data collection may take days or weeks. Data 
analysis of CD data is often completed in a matter of minutes, whereas NMR and x-ray 
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data can take months to analyze. CD spectroscopy, when performed using far UV 
wavelengths, is used to estimate protein secondary structure, to monitor changes in 
structure that may occur due to processing, or to monitor the protein for loss of structure 
in response to thermal stress.79,80 CD can be performed using other experimental 
parameters to gain different types of protein information. If one uses wavelengths in the 
near UV region information on tertiary structure can be obtained, based on aromatic 
amino acid absorption.81,82 The experiments described in Chapters 2-5 use CD with far 
UV wavelengths; therefore, far UV wavelength CD experiments are discussed below. 
 CD is performed by subjecting a sample to far UV wavelengths (190-250 nm), 
and collecting a signal that is generated from the difference in absorption between the 
left and right circularly polarized light.80 In the far UV region, the absorption is primarily 
due to the electronic transitions on the protein backbone, where π to π* and n to π* 
transitions are thought to occur along the amide groups of the protein.77,81,83 Differences 
in secondary structural characteristics of peptides and proteins can be studied using far 
UV CD, because changes in structure cause changes in the wavelength of light 
absorbed. The electronic transitions that can occur in an alpha helix produce a signal at 
approximately 222 and 209 nm; beta sheets absorb at 218 nm, and less ordered 
structure, around 195 nm.77 These signals do overlap77, but data analysis algorithms 
used to deconvolute the signals are available. Different algorithms produce different 
results, because they are based on different sets of protein structure calculations. Also, 
they use different basis sets, often consisting of protein structure determined by NMR or 
X-ray crystal data.84-88 For these reasons, it is recommended that algorithms and basis 
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sets are carefully chosen based on similarities to the protein or peptide being 
analyzed.86-88 
 Although CD cannot determine protein secondary structure with high precision, 
the technique can be especially useful for monitoring a protein’s loss in secondary 
structure in response to thermal stress; such a change is useful to monitor because the 
temperature at which the protein loses its secondary structure, its Tm, can be used to 
describe a protein’s stability.80 Experiments are performed by increasing the 
temperature of the sample, and scanning the sample at a single wavelength, and the 
change in signal is monitored. Using a two state protein folding assumption, the protein 
in solution will transition from being in the folded state, to the unfolded state, and the 
midpoint between the two is calculated to be the melt temperature (Tm) in °C.89,90 CD is 
used in this way in Chapters 2, 4, and 5, to compare thermal stabilities of native and 
modified therapeutic protein samples. 
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1.3 SUMMARY OF SUBSEQUENT CHAPTERS 
 Chapter 2 introduces a new concept for protein production and purification. In 
this new method, a protein that is not natively glycosylated can be produced in soluble 
and folded form, by modifying the protein DNA to include a non-native, N-linked 
glycosylation consensus sequence: N – X – S/T. The modified DNA is paired with an 
expression host that recognizes the signal for glycosylation, and the host glycosylates 
the protein. The non-native glycan structure is used as a temporary protein purification 
tag using lectin affinity purification. Enzymatic cleavage of the entire glycan may then be 
performed to completely remove the purification tag. The tagging and removal process 
has the advantage over currently used protein purification tags, because N-linked 
glycan removal does not require multiple non-native amino acid residues to be part of 
the final protein product. Two unique mutant human growth hormone proteins were 
designed, expressed, and studied to illustrate this concept. This method will mitigate 
commonly encountered difficulties during protein production, such as producing 
misfolded protein and the need to extract proteins from aggresomes. Analysis by 
circular dichroism indicates the method can be used to express and purify large 
amounts of properly folded protein.  
 
 Chapter 3 describes the use of glycosidases to modify the glycan moieties of 
glycoproteins, a method referred to as “glycan trimming”. Removal of either an entire 
glycan or removal of only specific sugar residues may prove useful when optimizing 
glycan properties of therapeutic glycoproteins. A model protein, Ribonuclease B, was 
used to demonstrate that trimming of the glycan structure does not destroy the 
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enzymatic activity of the protein, nor does it destroy the secondary structure of the 
protein. A novel enzymatic activity assay using Atmospheric Pressure-Matrix Assisted 
Laser Desorption Ionization Mass Spectrometry (AP-MALDI-MS) to detect the formation 
of products produced by the assay is described and is used to show the enzyme 
retained its activity after glycan trimming. These studies indicate glycan trimming may 
be broadly implemented without destruction of protein function and secondary structure. 
 
 Chapter 4 presents the application of glycan trimming methods introduced in 
Chapter 3, to glycoproteins containing sialic acid residues. A sialylated, therapeutic 
glycoprotein, erythropoietin, was expressed, purified, and then modified using glycan 
trimming to remove sialic acid residues. Removal of sialic residues that may be 
immunogenic will prove beneficial in the production of therapeutic glycoproteins like 
erythropoietin, and the studies presented in Chapter 4 show that sialic acid removal can 
be achieved using glycan trimming. Furthermore, the data indicate that the glycan 
trimming method can be used without decreasing erythropoietin’s thermal stability. 
Three additional, commercially available, sialylated glycoproteins were also subjected to 
the same glycan trimming and stability studies to illustrate the procedure can be broadly 
applied to sialylated glycoproteins without negatively impacting the thermal stability of 
the protein. The data clearly indicate that  the increase in melt temperature observed for 
erythropoietin post glycan-trimming is not just a feature unique to this protein. 
  
 Chapter 5 highlights the use of glycan trimming as one key component of a new 
method designed to prevent a common pathway of protein degradation: asparagine 
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deamidation. Deamidation is a major cause of aggregation in some vulnerable 
therapeutic proteins, such as human growth hormone. Three different human growth 
hormone variants were designed, expressed, and purified using methods similar to 
those described in Chapter 2, where non-native glycosylation was introduced using site 
directed mutagenesis. The glycosylation sites were placed at asparagine residues of 
growth hormone that are known to deamidate; the glycans provide steric bulk, which 
hinders the deamidation reaction. Secondary structure analysis of the mutant proteins 
indicated that the bulky glycan was negatively impacting the protein structure, prompting 
the use of enzymatic glycan trimming to trim the majority of the glycan from the protein. 
The resulting protein was found to have improved secondary structure after glycan 
trimming. The mutant proteins with trimmed glycans displayed improved thermal 
stability compared to a growth hormone standard. 
 
 Chapter 6 addresses a protein analysis problem encountered during data 
analysis of peptide mass fingerprinting experiments. Mass defect, the difference 
between nominal and monoisotopic mass, has been used to identify peptide peaks in 
mass spectra, when the mass defect value is within the range of values identified for 
peptides. The range can be used to filter the data, where any value outside of the 
defined range is rejected, since it does not have the correct mass defect to be a 
peptide. The range of possible mass defect values used in peptide data filters was 
calculated previously using a set of theoretical peptides, where every amino acid was 
used 5% of the time at random. To make mass defect filters more selective for real 
human peptides, two different sets of human proteins were digested in silico, and mass 
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defect values were calculated. The range determined using the human biofluid data was 
found to be narrower than the range of values previously established in the proteomic 
field. Using human protein data will increase the selectivity of mass defect peptide data 
filters used in proteomic data analysis.  
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CHAPTER 2 
THE NEW PROTEIN PURIFICATION HANDLE 
 
 Protein production via recombinant technology is an important tool across 
different industries and in life science studies. Producing large amounts of purified, 
folded protein, however, is a considerable challenge, and significant improvements to 
the purification schemes currently in use are needed to take full advantage of this 
powerful technology. We have designed a new protein purification platform that 
circumvents some of the most challenging complications that relate to purification, such 
as affinity tag removal, and generating natively folded, human proteins. In this novel 
protein purification scheme, a target protein sequence is modified to include a non-
native glycosylation site, and the protein is glycosylated during expression in eukaryotic 
cells. The glycan structure serves as a unique affinity tag, affording purified protein by 
lectin affinity chromatography. After protein isolation, the glycan may be removed, and 
the native protein sequence is regenerated. We have demonstrated this new method by 
expressing and purifying two novel human growth hormone mutants. Each protein 
contained a single, nonnative glycan used as an affinity tag, which was later removed. 
The resulting protein was analyzed for secondary structure using circular dichroism. 
This new method improves protein production by providing a new affinity purification tag 
used in generating purified, properly folded protein. 
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2.1 INTRODUCTION 
 Recombinant protein production is pivotal in multiple industries, e.g. 
pharmaceuticals, biomedical diagnostics, and life sciences research.1 In any setting, 
producing adequate quantities of highly purified protein is a formidable challenge. 
Recombinantly expressed proteins are commonly purified using one or more affinity 
tags, paired with a chromatographic method such as immobilized metal affinity 
chromatography (IMAC).2  Affinity tags usually consist of amino acid residues selected 
for their chemical behavior or binding epitopes, and are engineered into the protein 
sequence, commonly at the C or N terminus.3 The most widely used affinity tag is the 
polyhistidine tag (His-tag), consisting of a repeating sequence of H residues.2,3 
 His-tags may require additional amino acids near the tag location to direct tag 
removal using an exo- or endopeptidase.2-4 The enzymes used in tag removal from the 
C-terminus often leave 5 or more amino acids remaining at the cleavage site, which are 
not native to the protein sequence.2-4 His-tags may be partially or completely buried 
within the protein structure, making removal more difficult.4 These small tags have been 
reported to negatively impact the structure, activity, or binding of some proteins.5-10 
Unfortunately, some classes of protein are excluded from His-tag-IMAC purification, 
such as proteins with metal centers, whereas the affinity resin may bind the metal.5 
These observations direct researchers to search for alternative purification strategies.  
 Other affinity tags currently in use may be significantly larger than His-tags, such 
as the maltose-binding protein (MBP).11 These larger tags may be used in conjunction 
with a His-tag, or alone, but each tag is associated with unique structure or function 
effects, in addition to problematic tag removal procedures and protein solubility 
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issues.3,12 The development of a new strategy that overcomes commonly encountered 
problems in protein purification has the potential to make significant contributions to 
science and medicine. 
 To accomplish the aim of producing significant amounts of pure, folded protein, 
and to mitigate the complications described above, we have developed a new protein 
purification affinity tag. This method consists of incorporating a nonnative, asparagine-
linked (N-linked) glycan site into a nonglycosylated protein sequence. This change 
triggers enzymes to glycosylate the protein during eukaryotic expression, and the 
glycan provides a unique affinity tag, which can be exploited for protein purification. The 
protein is purified using lectin affinity chromatography (LAC). The glycan affinity tag may 
then be removed in its entirety using chemical or enzymatic means to produce the 
nonglycosylated product. A work-flow depiction is provided in Figure 1.  
 To illustrate the utility of this new protein purification approach, we designed two 
different, novel recombinant human growth hormone (rhGH) mutant proteins. Found 
endogenously, hGH is a non-glycosylated 22 kDa protein and is critical to proper growth 
and metabolism.13 Some children and adults have hGH deficiencies, and recombinantly 
expressed hGH has been an important biopharmaceutical treatment for these 
individuals.14-16 In the study herein, the two mutants were generated by adding a single 
N-linked glycosylation site  into the primary sequence of each mutant, using 
mutagenesis. The two mutants, D136N and D153N,N155T were designed to introduce 
consensus glycosylation sequences (N-X-T/S) at a disordered loop in the protein. When 
this consensus sequence is present in mammalian cell proteins, a glycan is attached at 
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the N.17 The D136N mutant’s glycosylation sequence is N(136)GS. The second 
mutant’s glycosylation sequence is N(153)TT. 
  
 
Figure 1. Protein production and purification scheme using an N-linked glycan as a temporary protein 
purification tag. The tag removal step uses PNGase F to completely remove the purification tag without 
leaving nonnative amino acids at the site, and also to restore the amino acid sequence to the naturally 
occurring D residues present in the native growth hormone sequence. 
  
 
These mutant proteins were expressed in Chinese hamster ovary cells (CHO), 
the most commonly used mammalian expression hosts, which are known for producing 
complex N-linked glycans at the consensus sequence.17 Purification was performed 
using lectin affinity chromatography (LAC), and the glycan was removed using Protein 
N-glycanase F (PNGase F). This endoglycosidase is known to cleave N-linked glycans 
from proteins, and in the process the N is converted to a D18, thus restoring the original 
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human growth hormone sequence, as shown in Figure 1. The pure, nonglycosylated 
product was characterized using gel electrophoresis (SDS-PAGE) and circular 
dichroism (CD) and was found to possess the desired molecular weight and secondary 
structure.
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2.2 EXPERIMENTAL PROCEDURES 
 
2.2.1 Materials 
The CHO-K1 cells were a gift from Dr. Jeff Krise (University of Kansas, 
Department of Pharmaceutical Chemistry, Lawrence, KS). Water was purified using the 
Millipore Direct Q-3 system (Millipore, Billerica, MA). All other materials were obtained 
from Sigma unless otherwise specified. All solutions were passed through a 0.2 µm filter 
prior to use.  
 
2.2.2 Construction of Recombinant Template Plasmid 
To create the rhGH plasmid, the hGH gene in mammalian vector (pCMV6-XL5) 
was purchased from Origene Technologies Inc. (number SC-3300088). The 5’ native 
signal sequence was included in the construct to enable secretion of the protein. The 
DNA encoded for a polyhistidine tag consisting of four histidine residues at the N 
terminus. Competent XL-1 Blue E. coli cells were transformed using the plasmid, then 
plated on Luria broth (LB) agar plates containing 100 mg/mL ampicillin. A colony was 
selected and used to inoculate 10 mL of selective LB medium. The resultant DNA was 
purified using a QIAprep Spin Miniprep Kit (QIAGEN, Valencia, CA) and quantified 
using a standard absorption assay on a Nanodrop® ND-1000 Spectrophotometer 
(Thermo Scientific, Wilmington, DE).  
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2.2.3 Site-Directed Mutagenesis of Glycosylation Site 
The plasmid was used as a template for modification to include an N-linked 
glycan. Primers (Integrated DNA Technologies, Inc., Coralville, IA) were designed to 
generate the rhGH-D136N mutant: (5’ to 3’) atg ggg agg ctg gaa AAT ggc agc ccc cgg 
act g (leading) and c agt ccg ggg gct gcc ATT ttc cag cct ccc cat (reverse), where the 
mutated bases are indicated using capital letters. Mutagenesis was performed using the 
QuikChange mutagenesis kit (Stratagene, La Jolla, CA). Primers were combined with 
the DNA template and the manufacturer’s protocol was implemented. 
The mutagenesis product was digested with 1 µL of DpnI enzyme (New England 
Biosciences, Ipswich, MA) to selectively destroy the template DNA. The product was 
then used to transform competent XL-1 Blue E. coli cells. Transformed cells were plated 
onto LB agar plates containing ampicillin, grown overnight at 37 °C, and a single colony 
was selected to inoculate liquid LB medium. After overnight growth, the resultant DNA 
was isolated and purified using the QIAprep Spin Miniprep Kit. All miniprep DNA was 
quantified as described above and sequenced by Northwoods DNA Inc., Bemidji, MN. 
The desired sequence was verified prior to transfection. 
 To generate the rhGH-D153N,N155T mutant, the same procedure was used, 
except two mutations were performed using one set of primers that encoded both 
mutations. The primer used to create the second mutant: (5’ to 3’) cc tac agc aag ttc 
AAC aca ACC tca cac aac gat gac gc (leading) and gc gtc atc gtt gtg tga GGT tgt GTT 
gaa ctt gct gta gg (reverse). DNA sequence was verified prior to transfection.  
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2.2.4 Cell Culture and Transfection 
CHO-K1 cells were seeded and maintained using complete high glucose 
Dulbecco’s Modified Eagle Medium (DMEM) (Thermo Scientific Hyclone, Logan, UT). 
The medium also contained supplemental MEM Non-Essential Amino acids 100x 
(ATCC, Manassas, VA), 10% fetal bovine serum (Mediatech, Inc. Manassas, VA), 100X 
penicillin/streptomycin (ATCC, Manassas, VA), and 150 mM L-Proline.19 Cells were 
maintained in T-75 flasks (BD, Franklin Lakes, NJ) with 24 mL of medium and kept at 37 
°C and 5% CO2. Passage was accomplished by two wash steps using pre-warmed 
phosphate buffered saline (PBS) alone and PBS containing trypsin to remove the 
adherent cells from the surface of the flask. After three minutes, the suspension was 
centrifuged at 3800 x g for 2 minutes in a 15 mL Falcon tube, the supernatant was 
removed via vacuum, and the cells were resuspended via gentle pipetting into 6 mL of 
the culture medium described above.  
Cells were allowed to grow to 50% confluency and then transfection was 
accomplished with 4 µg of mutated DNA and 20 µL of Turbofectin 8.0 transfection 
reagent (OriGene Technologies, Inc., Rockville, MD) per T-75 flask, per mutant protein. 
The supernatant was decanted after 24 hours and the medium replaced. After an 
additional 24 hours the supernatant was collected and concentrated to 0.5 mL using 
centrifugal filtration devices (Millipore, Billerica, MA) with a 10 kDa molecular weight cut 
off (MWCO) at 9000 x g. 
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2.2.5 Lectin Affinity Chromatography (LAC) Purification 
A cartridge (5-mL) containing Maackia amurensis leukoagglutinin (MAL) lectin 
resin (Qiagen, Valencia, CA) was equilibrated according to the manufacturer’s 
directions using the indicated binding/wash buffer. The concentrated supernatant (0.5 
mL) from a single supernatant collection was mixed with an equal volume of 
binding/wash buffer and loaded onto the column at 1 mL/minute. The column was 
washed using 50 mL of binding/wash buffer at 4 mL/min, and the rhGH was eluted into 
50 mL of elution buffer containing 200 mM lactose. The elution fraction was 
concentrated to approximately 1 mL as described above. The protein content was 
quantified using a standard Bradford assay. The rhGH protein was dialyzed using Slide-
A-Lyzer dialysis cassette with a 10 kDa MWCO (Pierce, Rockford, IL) into 10 mM 
sodium citrate and 150 mM sodium chloride, with 3 (1 L) exchanges. 
 
2.2.6 Immobilized Metal Affinity Chromatography (IMAC) Purification 
A prepared 5-mL column containing Chelating resin (GE Healthcare) charged 
with nickel was equilibrated. A sample of rhGH-D136N, which was purified using LAC 
and quantified with a standard Bradford assay, was mixed with an equal volume of 
loading buffer and was loaded onto the IMAC column. Loading buffer containing 50 mM 
TRIS-HCl, and 150 mM sodium chloride was adjusted with sodium hydroxide to pH 8.0 
and was filtered (0.2 µm). Rinsing buffer was the same, except it also contained 20 mM 
imidazole. The elution buffer was the same as the loading buffer, except it also 
contained 200 mM imidazole. The column was washed using 100 mL of loading buffer; 
rinsed using 50 mL of rinse buffer, and elution was performed via syringe using 16 mL 
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of elution buffer. The collected fractions were analyzed using SDS-PAGE and their 
protein content quantified using a standard Bradford assay. The procedure was 
repeated for the rhGH-D153N,N155T protein. 
 
2.2.7 SDS-PAGE Analysis 
 12% SDS-PAGE TRIS/glycine gels were generated for electrophoretic analysis. 
Protein samples were mixed with 2X reducing Laemmli loading buffer and water (1:3:3) 
and boiled for 15 minutes. The samples were loaded, and electrophoresis was 
performed at 123 V. Precision Plus unstained protein ladder (Bio-Rad, Hercules, CA) 
was utilized in separate lane(s) for molecular weight approximation. Gels were first 
stained using Coomassie (R-250) and then fully destained (using acetic acid:methanol 
2:3) prior to silver staining.  
 
2.2.8 Purification Tag Removal 
 Purified, glycosylated rhGH was treated with Protein N-Glycosidase F (PNGase 
F) from Elizabethkingia meningosepticum (CalBioChem, San Diego, CA) by adding 1 µL 
of 500 units/mL to approximately 2 mg of protein, and incubating for 24 hours at 37 °C. 
An aliquot of rhGH protein was loaded onto the MAL lectin cartridge using the 
procedure described above. The collected fractions were analyzed using both SDS-
PAGE and a Bradford assay to determine the final amount of purified, nonglycosylated 
rhGH. 
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2.2.9 CD Secondary Structure Estimation 
 The purified protein was diluted to 0.5 mg/mL in 10 mM sodium citrate and 150 
mM sodium chloride and placed in a jacketed, quartz, 1.0-mm pathlength sample cell. 
Far UV CD measurements were made using a Jasco J-715 spectropolarimeter (Tokyo, 
Japan) with an attached circulating water bath that was built in-house. Experiments 
were performed at 10 °C, with a sensitivity of 100 mdeg and scan speed of 10 nm/min. 
The experiments were conducted under constant nitrogen flow. Scans were performed 
from 260 to 180 nm. Multiple spectra were averaged, smoothed and baseline corrected 
by subtracting signal from background solutions prior to analysis. The publicly available 
DICHROWEB server was used, with the CDSSTR algorithm, to calculate the percent 
protein secondary structure. 
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2.3 RESULTS AND DISCUSSION 
Protein production methods aim to generate large amounts of pure and natively 
folded protein. This is a difficult goal to achieve. Challenges common to protein 
purification exist, such as optimizing the purification method and ensuring proper protein 
folding . To elude these issues, we propose a novel protein purification strategy to 
support the production of pure, folded protein. The strategy consists of introducing a 
nonnatural glycosylation site into the protein sequence, expressing the protein in 
eukaryotic cells to connect glycan tag and protein, then purifying the protein using lectin 
affinity. Figure 1 illustrates these steps. 
 
 
Figure 1. Protein production and purification scheme using an N-linked glycan as a temporary protein 
purification tag. The tag removal step uses PNGase F to completely remove the purification tag without 
leaving nonnative amino acids at the site, and also to restore the amino acid sequence to the naturally 
occurring D residues present in the native growth hormone sequence. 
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2.3.1 Novel Protein Purification Platform 
To demonstrate the utility of purifying protein using this approach, we expressed 
two mutant, glycosylated forms of recombinant human growth hormone in CHO-K1 
cells, and purified the protein using lectin affinity chromatography. In Figure 2, the 
sequence of the native hGH and the two glycosylated mutants generated in this study is 
shown. The two mutants each contain the “consensus sequence” (N-X-S/T), which is 
recognized by glycosylating enzymes within eukaryotic cells as a signal to attach, and 
then modify, an N-linked glycan.20-21 The resulting glycan was used as an affinity tag to 
purify the growth hormone with lectin affinity chromatography. After purification, the 
glycan was enzymatically removed using PNGase F, as illustrated in the Tag Removal 
step in Figure 1 above. The tag removal step relies on the inherent enzymatic activity of 
PNGase F, which converts an N residue to a D during the N-linked glycan removal 
reaction.18 The conversion to an aspartic acid actually restores the purified rhGH-D136N 
protein to its native sequence, which naturally contains a D at that amino acid position. 
The original protein sequence and genetic modifications are given in Figure 2.  
 
 
 
Figure 2. Verified DNA sequence of modified rhGH mutants. The first mutant, rhGH-D136N, was modified 
to include the consensus sequence for N-linked glycan incorporation, using a single point mutation. The 
second mutant, rhGH-D153N,N155T, was modified to include the consensus sequence with two point 
mutations.  
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After glycan removal, Mutant I contained the native hGH sequence. Mutant II, the 
rhGH-D153N,N155T protein, contained only a single amino acid variant from the native 
sequence, with T-155 in place of an N residue. This modification is necessary to meet 
the requirements of the consensus sequence for N-linked glycosylation. These changes 
made to the protein sequence to engineer the glycan affinity tag require significantly 
fewer modifications than other purification tags currently in use, which often require 
many nonnative amino acids to be incorporated with the protein sequence.2-4  
 
2.3.2 Protein Analysis 
The glycosylated, rhGH proteins were analyzed before and after purification by 
lectin affinity, using SDS-PAGE. In Figure 3a, the lane to the right of the molecular 
weight marker lane represents the media prior to purification. A very large band at 
approximately 70 kDa is visible along with several other bands, including a faint band 
between the 20 kDa and 25 kDa markers, which matches the molecular weight of 
glycosylated growth hormone. The largest band is the correct molecular weight for 
bovine serum albumin, which is added to the cell growth medium. This lane clearly 
indicates, as expected, that prior to purification the protein of interest is present in a 
complex mixture of other proteins, whose concentrations are high, compared to the 
expressed protein. The rhGH bands positioned slightly above the 20 kDa marker are 
more evident after purification using LAC, as observed in the two lanes on the right in 
Figure 3a. Lane 3 is the band resulting from analysis of rhGH-D136N, and lane 4 
contains rhGH-D153N,N155T.  
 48 
A second analysis of rhGH-D136N using SDS-PAGE was silver stained for 
increased sensitivity (Figure 3b). There is a single, distinct band in the lane containing 
rhGH-D136N, at the expected molecular weight for glycosylated rhGH. No other 
significant bands were visible using the more sensitive silver staining procedure, 
indicating a purified protein product is present.  
 
 
Figure 3a. 
 
 
Figure 3b. 
 
 
Figure 3. SDS-PAGE analysis of novel rhGH proteins. (a) Sample in lane 2 is an aliquot of collected 
cellular supernatant, lanes 3 and 4 contain rhGH-D136N and rhGH-D153N,N155T that have been purified 
using lectin affinity chromatography, respectively. Coomassie stain was used. (b) Right lane is a sample 
of purified rhGH-D136N, silver stain procedure was used.  
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2.3.3 Protein Quantitation and Comparison of Purification Methods  
Purified rhGH proteins were quantified using a standard Bradford assay. The 
resulting values are displayed in Table 1. From a single 24-hour collection of the cell 
growth media (supernatant), 1.67 mg of glycosylated rhGH protein was recovered from 
24 mL of medium, as determined after LAC purification.  
 
Table 1. Bradford Assay Results for Protein Concentration  
 
 
 
The notation of n/d indicates not detected, * indicates the protein sample had been deglycosylated using 
PNGase F. 
 
To compare this affinity purification method to purification with a polyhistidine tag, 
the purified rhGH-D136N, which contained a polyhistadine tag at the N-terminus, was 
also purified using an IMAC column. The collected fractions were concentrated as 
described above. No protein was detected in the second wash fraction, the rinse 
fraction or the elution fraction, as indicated by n/d for not detected within Table 1. 
Analysis of the first wash IMAC wash fraction (wash I) showed the rhGH-D136N protein 
concentration to be 1.27 mg/mL, after concentration to approximately one mL. This 
study indicates that the metal affinity method was ineffective at binding the polyhistidine 
tagged protein, since the tag should have bound to the column and only eluted during 
the “elution” step.  
The rhGH-D136N protein sample was deglycosylated using PNGase F, and then 
again loaded onto the LAC cartridge. Any protein that was still glycosylated after 
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reaction with PNGase F would bind to the column, as demonstrated above. Therefore, 
the LAC method could be used to separate glycosylated from deglycosylated protein 
and quantify the amount of protein that had been deglycosylated. The only detectable 
protein was found in the LAC wash fraction, and after sample concentration to one mL 
the amount of protein detected was 1.01 mg/mL. Similar results were obtained for the 
rhGH-D153,N155T protein and can be found in Table 1. 
 
2.3.4 Secondary Structural Measurements 
Secondary structure of the deglycosylated protein, containing the native hGH 
sequence, was characterized using far-UV circular dichroism. The spectra are shown in 
Figure 4. Minima in the spectra are observed at wavelengths 209 nm and also at 222 
nm, indicating alpha helical structure.  
 
 
 
Figure 4: Far-UV CD data for glycosylated human growth hormone (▪▪) and deglycosylated proteins 
rhGH-D136N (in gray) and rhGH-D153N,N155T (in black). The curves corresponding to the 
deglycosylated proteins indicate alpha helical character is dominant after removal of the glycan 
purification tag. 
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 The far-UV scan of the rhGH protein was compared to data in the literature.21-24 
The spectra for the deglycosylated proteins indicate that a large portion of the 
secondary structure present in the protein sample is alpha helical in character. 
Endogenous hGH is known to have alpha helices accounting for 50-60% of secondary 
structural characteristics.21-24 To quantify the helical content of the rhGH sample, the CD 
data was analyzed using the publicly available, web-based DICHROWEB program.25-28 
The helical secondary structure calculation results for deglycosylated rhGH-D136 are 
54% and rhGH-D153,N155T, 59%, as displayed in Table 2. These values are within the 
range of acceptable values found in literature for other hGH samples.21-24   
 
Table 2: Secondary structure of deglycosylated rhGH as predicted by DICHROWEB. 
 
 
 
2.3.5 Advantages of this new method 
 The approach to protein production and purification described above has several 
benefits over other purification methods that are currently in use, such as using IMAC 
and His-tags. Here, we have generated a protein purification affinity tag, but the tag is 
not restricted to the protein’s termini, as glycans can be incorporated into the protein at 
any point, including the termini, if desired. The tag could be specifically inserted into a 
disordered loop of the protein, or far away from active sites, or at the termini. Other 
affinity tags are practically restricted to either the N or C terminus. The ability to select 
the location of the purification tag is advantageous because proteins such as hGH may 
have binding motifs close to or including the terminal parts of the protein.23-25  
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 In addition, other purification tags may require additional amino acid sequences 
to direct removal of the tag by proteases, but glycans can be partially or completely 
removed without this additional requirement. In this method, PNGase F was used to 
remove the glycan purification tag, leaving no additional amino acids on the protein. 
This tag removal process may prove beneficial over currently employed tag removal 
methods, where several nonnative amino acids often remain on the protein sequence 
after the tag removal steps are completed, and in some cases the additions negatively 
impact protein folding or activity.5-10 
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2.4 CONCLUDING REMARKS  
The utility of this novel protein purification method has been demonstrated by 
producing two properly folded, purified, and novel human growth hormone mutants. The 
proteins were produced in soluble and folded form using an eukaryotic host, as opposed 
to the misfolded and aggregated forms often encountered using E. coli.32 The lectin 
affinity purification method, used in conjunction with the glycan affinity tag, produced 
highly purified protein in good yield; by comparison, the 4-His-tag on the N terminus of 
the protein was an ineffective tag for IMAC purification. Finally, once the glycan affinity 
tag was removed, the protein adopted the proper degree of alpha helical content, 
supporting the assertion that the native structure was retained.  
The use of a glycan purification tag has several benefits over current affinity 
labels. It can be engineered into the protein sequence where desired, instead of being 
forced onto one of the termini. Additionally, the tag addition site can be chosen such 
that after tag removal, no nonnative amino acids will remain on the final protein product. 
This approach to protein purification has the potential to make a significant impact on 
medicine and life science research by providing an alternative strategy for protein 
production and purification. 
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2.5 FUTURE WORK 
 Both human growth hormone protein mutants described in this chapter will be 
subjected to proteolytic digestion and high resolution mass spectrometric analysis. 
These studies will provide ancillary support that we have purified the protein of interest, 
and they can be used to characterize the glycan affinity tag. The sample preparative 
steps will employ glycopeptide and peptide analysis, as described in Chapter 1, section 
1.2.3.1. 
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CHAPTER 3 
 
POST-PROTEIN EXPRESSION ENZYMATIC GLYCAN TRIMMING 
 
 Recombinant glycoproteins present unique challenges to biopharmaceutical 
development, especially when efficacy is affected by glycosylation. In these cases, 
optimizing the protein’s glycosylation is necessary, but difficult, since the glycan 
structures cannot be genetically encoded, and glycosylation in non-human cell lines can 
be very different from human glycosylation profiles. We are exploring a potential 
solution to this problem by designing enzymatic glycan optimization methods to produce 
proteins with useful glycan compositions. To demonstrate viability of this new approach 
to generating glycoprotein-based pharmaceuticals, the N-linked glycans of a model 
glycoprotein, ribonuclease B (RNase B), were modified using an α-mannosidase to 
produce a new glycoprotein with different glycan structures. The secondary structure of 
the native and modified glycoproteins was retained, as monitored using circular 
dichroism. An assay was also developed using an RNA substrate to verify that RNase B 
had indeed retained its function after being subjected to the necessary glycan 
modification conditions. This is the first study that verifies both activity and secondary 
structure of a glycoprotein after enzymatic glycan trimming for use in glycoprotein 
therapeutic development methods. The evidence of preserved structure and function for 
a modified glycoprotein indicates that extracellular enzymatic modification methods 
could be implemented in producing designer glycoproteins for therapeutic use.  
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3.1 INTRODUCTION 
Glycoprotein therapeutics are currently administered for treatment and/or 
prevention of diseases. Trends indicate that glycoproteins will continue to account for 
the majority of new biopharmaceuticals.1 Protein and glycoprotein-based therapeutics 
are being pursued in part, due to their known, specific mechanisms of action. 
Glycoprotein therapeutic use has been made possible by the rapid development in 
recombinant glycoprotein expression techniques over the last few decades. Mammalian 
cell lines, used for glycoprotein expression, are capable of producing proteins with 
complex-type asparagine linked (N-linked) glycans, but the glycan compositions are 
heterogeneous.2-3 Other expression hosts such as yeast and insect cells are not 
equipped with the cellular machinery to create the complex N-linked glycans found in 
human glycosylation profiles without genetic modifications.4-5  
N-linked glycans are of particular importance for glycoprotein pharmaceutical 
production, because they have shown to directly influence the glycoprotein’s properties 
such as stability, folding, charge, and even function.6-9 For example, glycodelin in 
human tissues exists with two main glycoforms: glycodelinA (GdA), which is fully 
sialylated, and glycodelinS (GdS), which lacks sialic acid, but possesses numerous 
fucose residues.10 It is proposed that the negatively charged sialic acid residues of GdA 
activate the T-cell suppressing activity of this glycoprotein, whereas the neutral glycans 
of GdS merely mask the active site of the amino acid backbone and therefore prevent 
immune suppression.11-12 The addition of sialic acid residues to N-linked glycans is 
particularly important in glycoprotein therapeutic construction as these residues have 
been shown to not only promote activity, but increase in vivo circulation half-life as well, 
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such is the case with erythropoietin.13-14 These examples demonstrate that a 
glycoprotein developed for pharmaceutical applications must possess the N-linked 
glycan motifs that will support the desired pharmacological properties.  
Researchers interested in radically changing glycan structures of glycoproteins, 
to control pharmacological properties, currently use methods that modify the 
intracellular glycosylation machinery of the expression host to include non-native 
glycosylating enzymes (glycoenzymes) into the cell’s Golgi apparatus.15-16 Recently 
Hamilton, et al., engineered the yeast Pichia pastoris to produce glycoproteins with 
biantennary, complex N-linked glycans.17 This is a seminal advance that shows yeast 
expression systems could be used to generate glycoproteins with “human-like” 
glycosylation; however, the glycans consist of biantennary, complex N-linked structures, 
and lack the higher branching observed in some naturally occurring mammalian 
glycoproteins.18 Another obstacle to pursuing this type of intracellular glycosylation 
remodeling includes genetically engineering a non-native glycoenzyme to localize 
correctly within the cellular machinery. This task is not trivial, and the cellular location for 
some glycosylating enzymes hasn’t been determined precisely.19 The majority of 
glycoenzymes are type II membrane proteins that need to become anchored into the 
Golgi membrane.16 This localization event is based on the N-terminus of the enzyme 
and is not always predictable.20 Assuming the new glycoenzyme is properly localized, 
there may be additional genetic work that must be done, such as silencing the genes for 
competing glycoenzymes, and some gene disruptions cause the host to die.21 While 
intracellular glycosylation remodeling is a powerful and important approach to 
engineering glycoproteins with optimal glycosylation, it still has many barriers to cross 
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before it can be implemented routinely and cost effectively. For these reasons, we 
propose a complementary approach to designing glycoprotein therapeutics with novel 
glycosylation; this strategy is described in Figure 1. 
 
 
 
Figure 1: Extracellular enzymatic glycan optimization work-flow for glycoprotein therapeutic agents. 
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 In this new approach, glycoenzymes, and their required cofactors, are used to 
optimize glycans of glycoproteins in a step-wise fashion after protein expression and 
purification has been completed. The basic premise for extracellular enzymatic glycan 
optimization has been demonstrated previously. Most notably, it was completed by 
Witte, et al., who engineered a sialyl Lewis X moiety on the single glycosylation site of 
ribonuclease B in place of its natural high mannose glycan.22 We implemented a similar 
enzymatic approach as the first step in our work-flow, and follow it with structural and 
functional assays on the newly engineered protein (Figure 1). Direct mass spectrometric 
(MS) analysis ensures the desired glycan modifications occurred, while circular 
dichroism (CD) spectroscopic analysis is useful in monitoring for disruptions to the 
secondary structure of the protein portion. The final step in the work-flow consists of 
monitoring the glycoprotein’s function to ascertain that the desired activity is indeed 
retained, since any glycoprotein modified for therapeutic use must verifiably retain its 
activity.  
 The study presented here uses ribonuclease B (RNase B) as a model 
glycoprotein to demonstrate the use of enzymatic glycan trimming methods for the 
production of structurally and functionally conserved protein. This protein is a useful 
model system that allows straightforward analysis of structure and function. RNase B is 
a 15 kDa enzyme that contains a single N-linked glycosylation site at N34, and consists 
of both α-helices and β-strands in its structure.23-24 Removal of mannose residues from 
the high mannose N-linked glycans on RNase B was performed with an α-mannosidase 
isolated from Jack Bean.25-26 The removal of mannose residues from high-mannose N-
linked glycans may prove to be a desirable modification, since glycoproteins with high 
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mannose glycans have a short in vivo circulation half-life.27-28 The native and modified 
glycoprotein samples were then analyzed with respect to composition, structure, and 
function. A work-flow diagram of the functional assay is shown in Figure 2. The 
retention of activity is the cornerstone for developing useful glycoprotein therapeutic 
agents with designer glycosylation. The study described herein supports previous work 
that extracellular glycosylation remodeling is a useful approach to generating 
glycoproteins with custom-made glycosylation; and this is the first demonstration that 
enzymatic glycan trimming methods are viable for generating glycoproteins for 
pharmaceutical applications.  
 
 
Figure 2. Novel RNase B activity scheme. 
 
 63 
3.2 EXPERIMENTAL PROCEDURES 
 
3.2.1 Materials 
 HPLC grade methanol was obtained from Thermo Fisher Scientific (Fairlawn, 
NJ), RNA substrate was obtained from Integrated DNA Technologies (Coralville, IA), 
and sodium bicarbonate was purchased from Fluka (Milwaukee, WI). Water was purified 
using the Millipore Direct Q-3 system (Millipore, Billerica, MA), and all other reagents 
were purchased from Sigma Aldrich (St. Louis, MO). 
 
3.2.2 Glycan Modification 
 Approximately 500 µg of bovine pancreatic RNase B was added to 300 µL of 10 
mM NH4HCO3 buffer, and the solution was adjusted to pH 5.0 using HCl. A 
commercially available α-mannosidase was added in an enzyme:glycoprotein ratio of 
1:1000 (mol/mol), and incubated for 72 hours at 37°C. A second, identical sample of 
RNase B was treated to the same conditions, except the mannosidase was not added. 
 
3.2.3 Mass Spectrometry 
A portion (150 µL) of the glycoprotein samples were subjected to DTT in excess 
for 1 hour at 60°C, then diluted to 5 µM using 80:20 MeOH:H2O, and 0.5% acetic acid. 
MS data were collected using a Thermo Fisher Scientific (San Jose, CA) hybrid linear 
ion-trap Fourier transform ion cyclotron resonance mass spectrometer (LTQ-FT-ICR-
MS). Direct infusion was performed at 2 µL/min for electrospray ionization in the positive 
ion mode. The spray voltage was set at 2.8 kV, and the N2 sheath gas was set to 10.0 
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psi. Ion desolvation was aided by heating the ion transfer tube to a temperature of 
250°C. Resolution was set to 100,000 for the ion m/z 400. All parameters were adjusted 
using the instrument software Excalibur, version 2.0. 
 
3.2.4 Circular Dichroism 
 Far UV circular dichroism measurements were made using a Jasco J-715 
spectropolarimeter (Tokyo, Japan) with an attached circulating water bath. Portions of 
the native and the modified glycoproteins were diluted with water to a final concentration 
of 71µM, and 250 µL of sample was placed in a jacketed, quartz, 1.0 mm pathlength 
sample cell. Experiments were performed at 10°C, with a sensitivity of 100 mdeg and 
scan speed of 20 nm/min. The experiments were conducted under constant nitrogen 
flow. Scans were performed from 260 to 190 nm in triplicate. All spectra were smoothed 
and baseline corrected by subtracting signal from background solutions prior to 
analysis. The publicly available DICHROWEB server was used, with the SELCON3 
algorithm, to estimate the percent glycoprotein secondary structure for α-helices, β-
strands, β-turns, and disordered structural components.29-32 
 
3.2.5 Activity Assay 
 RNA substrate, 5’-GGUAG-3’, was diluted to 0.1 mg/mL with RNase free water. 
A small amount of the RNA substrate was mixed with native RNase B, in an 
enzyme:substrate ratio of 1:10,000 (mol/mol) and allowed to react for 5 minutes. The 
reaction was quenched using 0.1% (v/v) diethyl pyrocarbonate.33 One µL of product was 
combined with one µL of MALDI matrix (15 mg/mL dihydroxybenzoic acid in 80:20 
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acetonitrile:water), spotted, and allowed to dry at 60 °C for thirty minutes. The reaction 
was repeated using the modified RNase B sample. Mass spectral data were collected in 
negative ion mode using a quadrupole ion trap mass spectrometer (LCQ Advantage, 
Thermo Fisher Scientific, San Jose, CA) and an atmospheric pressure matrix assisted 
laser desorption ionization (AP-MALDI) source (MassTech, Columbia, MD). The ion 
transfer tube was heated to 250 °C to assist with desolvation of ions. The nitrogen laser 
was operated at 337 nm, with a 4 nsec pulse width, and controlled using AP Maldi 
Target software, version 3.4. The voltage applied to the MALDI plate was set to 3.0 kV. 
A total of 333 laser shots were averaged into one spectrum prior to data analysis. Data 
analysis was performed using the instrument software Excalibur, version 1.3.  
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3.3 RESULTS 
 
3.3.1 Enzymatic Glycan Modification and Verification by MS 
 Proof of principle experiments, outlined in the work-flow depicted in Figure 1, 
were conducted using RNase B as a model glycoprotein. RNase B has five naturally 
occurring glycoforms, ranging from five to nine mannose residues (man5-man9), at its 
single N-linked glycosylation site.34-35 RNase B was reacted with α-mannosidase to trim 
the glycans. This extracellular glycoenzyme reaction completed the first step in the 
glycan optimization method.  
The second step in Figure 1 is to verify the effectiveness of the enzymatic 
reaction by obtaining glycan compositional data for the glycoprotein. The model 
glycoprotein’s single N-linked glycosylation site allowed for direct analysis using mass 
spectrometric techniques. This was accomplished by analyzing the whole glycoprotein 
with electrospray ionization in the positive ion mode, using an FTICR-MS. RNase B 
contains four disulfide bonds, and if reduced, charge states are observed well within the 
range the required m/z range.36 Reduction of disulfide bonds was performed with DTT in 
excess. Upon analysis of the reduced native and modified glycoproteins, a distribution 
of charge states, +8 through +11, were observed. (See insets of Figure 3). The +9 
charge state peaks for both the native and modified RNase B samples are labeled with 
measured m/z values and respective glycoform structures in Figures 3a and 3b. The 
predicted and observed m/z values for glycoforms are listed in Table 1. The five 
naturally occurring glycoforms of the native glycoprotein were observed in all charge 
states detected, with man5 accounting for the largest peak for the native glycoprotein. 
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Man5, observed at m/z 1656.69 in Figure 3a, has been described as the most abundant 
glycoform species for RNase B, reportedly composing nearly half of the population.37 A 
man4 glycoform was present in the commercially available sample, as confirmed by 
additional mass spectrometric analysis, performed using the same procedure described 
in section 3.2.3. 
 
 
Figure 3. FT-ICR-MS data for the +9 charge state on intact RNase B. Insets: full MS data showing charge 
state distribution. Peaks are labeled with m/z values for the most abundant isotopes and glycan 
compositions for each of the protein’s glycoforms. Symbols:  = sodiated adducts,  = N-
acetylglucosamine, and  = mannose. (a) Native RNase B. (b) Modified RNase B, treated with α-
mannosidase from Jack Bean for 72 hours, at 37°C, and pH 5.0. The glycoforms Man5-Man9 are not 
observed in the modified glycoprotein. 
 
The glycoforms observed in the modified RNase B sample were expected to 
differ from the native protein by possessing fewer mannose residues, due to the 
reaction with the exoglycosidase, α-mannosidase. This glycoenzyme was expected to 
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sequentially trim terminal mannose residues from the glycan structures of RNase B, 
based on characterization of its specific action.25,26,38 Mass spectrometry experiments 
were repeated using the modified RNase B sample, and results are depicted in Figure 
3b. In the +9 charge state, three glycoforms of the modified glycoprotein are detected: 
man2 at m/z 1602.45, man3 at m/z 1620.57, and man4 at m/z 1638.57. These peaks are 
labeled with their assigned glycan structures, based on the calculation of exact mass for 
each species. The predicted and observed m/z values for the modified glycoprotein 
peaks in the +9 charge state are displayed (Table 1) and values for both the fully 
protonated and the significant sodiated adducts are included. Both spectra contained 
sodiated adducts of species, and these are indicated with a symbol ().  
 
Table 1: Predicted and observed m/z values for native and modified RNase B in the +9 charge statea 
 
 
aSymbols:   = N-acetylglucosamine,  = mannose, N = native glycoprotein, P = protonated only 
species, M = modified glycoprotein, S = sodiated adducts, and n/a = not applicable -- these ions were not 
detected. 
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3.3.2 Secondary Structural Measurements 
 The third step in the work-flow, outlined in Figure 1, consists of monitoring 
glycoproteins for changes in protein structure. Monitoring for these changes is a 
necessary step, because a functional assay alone may not be a reliable indicator of an 
intact glycoprotein; since some species with alterations in protein folding can still be 
enzymatically active.39-40 CD spectroscopic analysis was performed on the native and 
modified glycoprotein samples in the far UV wavelength region (260-190 nm) to monitor 
for differences in secondary structure. The data points were plotted in overlay mode, as 
shown in Figure 4, and although both samples produced broad signals, an indication of 
an αβ protein, a slight increase in signal over the α helical wavelength region (~209 nm) 
is present in the modified glycoprotein sample.  
 
 
Figure 4: Far-UV CD data of overlaid spectra for native and modified RNase B glycoprotein. The modified 
protein retains very similar secondary structure to the native protein. 
 
 The results were analyzed using the web-based DICHROWEB server,29-32 and 
the percent secondary structure estimation results are presented in Table 2 as 
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calculated by the server. Native RNase B was estimated to have α-helices accounting 
for 12% and 10% of its overall structure, and 17% and 10% of its structure was 
attributed to β-strands. The modified RNase B was characterized as containing 18% 
and 13% α-helical and 14% and 9% β-stranded structures. The rest of the protein was 
estimated to contain turns and disordered structure. For each of the features identified 
for this protein, the percent contributions are similar for the native and modified 
structure, and the absolute differences in the values are within the margin of error of the 
measurement. These data demonstrate that the modified protein had similar secondary 
structure to the native protein.  
 
Table 2. Percent secondary structure of RNase B as predicted by DICHROWEB. 
 
 
3.3.3 RNase B Functional Assay 
 The final step in the glycan optimization work-flow includes a functional assay 
that compares the function of the modified glycoprotein to that of the native 
glycoprotein. This step is imperative if a glycoprotein with modified glycosylation is to 
become an active pharmaceutical agent. The model glycoprotein chosen for this study, 
RNase B, is known to catalyze the cleavage of RNA substrates via hydrolysis of the 
3’,5’-phosphodiester bonds. The modified RNase B sample’s ability to catalyze RNA 
depolymerization was not expected to be negatively affected by enzymatic glycan 
trimming, as the removal of mannose residues is thought to promote RNase B activity.26 
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 In addition, the nonglycosylated analog to RNase B, RNase A, is known to also 
perform similar functions.41 Never-the-less, the functional assay is still a critical 
component of the work flow, because the sample handling conditions necessary to 
achieve the glycosylation remodeling could, in principle, deactivate the protein. To 
demonstrate retention of activity after extracellular glycan modification, an RNA 
substrate with the sequence 5’-GGUAG-3’ was reacted with the native glycoprotein, and 
then the experiment was repeated with the modified glycoprotein, illustrated in Figure 2. 
The products produced from cleavage of the RNA substrate were detected using AP-
MALDI, coupled to a quadrupole ion trap mass spectrometer. In Figure 5, AP-MALDI-
MS data acquired in the negative ion mode are shown for the intact RNA substrate 
(Figure 5a), along with the RNA substrate after reacting with the native RNase B (Figure 
5b). Figure 5c shows the RNA after reacting with the RNase B that has undergone 
enzymatic glycan trimming.  
 The base peak in Figure 5a, at m/z 1607, represents the intact substrate with 
sequence 5’-GGUAG-3’, and its sodiated adducts, for example at m/z 1629, are labeled 
with a symbol (). In Figure 5b, the products of the native RNase B reaction are 
illustrated. The peaks at m/z 611 and m/z 995 indicate that the RNA substrate was 
cleaved between the uridine and adenosine substituents, leaving the two nucleotides 
with base compositions AG and GGU respectively. No intact substrate was detected in 
either experiment as indicated by the arrows in Figure 5b and 5c. The data in Figure 5c 
matched the data in Figure 5b, thus demonstrating that the native and the modified 
glycoproteins were both effective at cleaving this particular RNA substrate, under the 
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conditions tested. These results indicate that the glycoprotein RNase B can undergo the 
extracellular enzymatic glycan trimming process, while retaining its desired function. 
 
 
 
Figure 5: AP-MALDI-MS data of (a) intact RNA substrate with the sequence 5’-GGUAG-3’, (b) nucleotide 
products from RNA substrate digestion, after reaction with native RNase B and (c) nucleotide products 
from RNA substrate digestion, after reaction with modified RNase B. The MS data shows that the RNase 
cleavage reaction was complete for both the native RNase B and modified RNase B. Symbols:  = 
sodiated adducts. 
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3.4 DISCUSSION  
A model glycoprotein, RNase B, was chosen to demonstrate the utility of 
extracellular enzymatic glycan trimming. RNase B is an ideal protein for these studies 
because of its small size, consisting of 124 amino acids, and its single N-linked 
glycosylation site, at N34. Additionally, the glycosylation on this protein is well 
characterized. The asparagine is linked to one of five glycoforms that consist of five to 
nine mannose residues with man5 accounting for nearly half the naturally occurring 
population.34-37 The glycan modification reaction, removal of mannose residues, is very 
relevant to pharmaceutical development, since high mannose glycans are known to 
contribute to a short in vivo circulation half life; thus enzymatic removal may be a 
desirable first step in glycan remodeling.27,28  
Using the RNase B protein as a model, we demonstrated a new approach for 
development of designer glycoprotein therapeutics with custom-made glycosylation. 
The approach capitalizes on previous research that has demonstrated extracellular 
glycosylation remodeling of whole proteins is possible22,25, and we implement that 
principle in the first step of a four-step work-flow for therapeutic glycoprotein 
development and characterization. In our approach, MS analysis of the whole protein 
(Step 2 in the work-flow) was an efficient method of characterizing the success of the 
enzymatic reaction. Direct analysis by ESI-FT-ICR-MS served as a useful way to 
monitor the enzymatic reaction and to optimize the reaction conditions, since no 
purification, and minimal sample preparation, are required for this analytical approach. 
Mass spectral analysis has been shown to be a very reliable method to characterize 
protein glycosylation, and even very large proteins, with multiple glycosylation sites, can 
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be studied using this approach, if a protease digestion step is incorporated so that 
glycopeptides are analyzed.42-46 
In addition to modifying and characterizing the glycosylation composition, the 
process of extracellular glycosylation remodeling for therapeutic glycoprotein 
development must also address the need for validating that the protein structure and 
function are retained. Herein, we have implemented both a structural assay, using CD, 
and a novel functional assay that monitors the enzymatic cleavage of RNA. While the 
structural and functional assays could take on various forms, depending on the 
glycoprotein target of interest, these components are important steps in validating that 
the modified glycoprotein is still useful for its intended purpose.  
In the structural experiments, CD was useful for identifying that the modified 
protein structure was generally very similar to that of the native protein, although a slight 
signal increase occurred in the α-helical region, at wavelength 209 nm, for the modified 
glycoprotein. Perturbations to RNase B’s secondary structure with changes in glycan 
composition have been reported in the literature; however, any observed changes were 
described as being statistically insignificant.38,47-49 Although the CD data illustrates an 
increase in α-helical character for the modified glycoprotein, the calculations for 
secondary structural characterization are within the margin of error of the data for the 
native protein, and thus are not considered significant.  
The final and most critical aspect of extracellular glycosylation remodeling for 
therapeutic glycoprotein development is assessing the function of the modified 
glycoprotein. For RNase B, as well as for other enzymes, an enzymatic assay is an 
obvious choice for functional validation. We chose to detect the nucleotide products of 
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RNase B’s enzymatic reaction with an RNA substrate using AP-MALDI-MS. MALDI 
techniques are an advantageous detection strategy because they use very little sample 
(1 µL in this case); they afford rapid analysis, and provide high sensitivity and selectivity. 
Additionally, AP-MALDI ionization, which is used in these experiments, has shown to be 
an even “softer” ionization source than conventional MALDI; thus the RNA was not 
expected to fragment during the ionization process.50 Other in vitro (or in vivo) methods 
of assessing function are also possible, as well as other detection methods for 
analyzing the results. In our assay, the AP-MALDI-MS data clearly and rapidly revealed 
that RNase B, after enzymatic glycan trimming, retained its function, compared to the 
unmodified protein.  
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3.5 CONCLUDING REMARKS 
The studies described above lay the groundwork for using extracellular 
glycosylation remodeling in therapeutic glycoprotein development. This approach could 
show significant advantages to intracellular glycosylation remodeling (which is currently 
the gold standard in optimizing protein glycosylation), because the enzymatic conditions 
can be more carefully controlled and optimized when they are conducted on the lab 
bench, as opposed to inside the cell. We are currently pursuing this strategy in 
synthesizing several glycoprotein-based pharmaceuticals with custom-designed 
glycosylation profiles.  
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CHAPTER 4 
OPTIMIZING SIALIC ACID CONTENT VIA GLYCAN TRIMMING: 
RETAINING THERAPEUTIC GLYCOPROTEIN THERMAL STABILITY  
 Optimized protein modifications, such as N-linked glycosylation structures, are 
necessary to attain desired pharmacological properties of some biopharmaceuticals. 
Sialic acid residues and derivatives, including N-glycolylneuraminic acid (Neu5Gc), are 
glycan building blocks often incorporated into the N-linked glycans during production of 
therapeutic glycoproteins. Neu5Gc is problematic because it is immunogenic to 
humans, and can induce the formation of antibodies to complex type N-linked glycan 
epitopes. Attempts at preventing Neu5Gc incorporation have focused on gene silencing 
within the expression host, or avoiding expression host systems known to produce large 
amounts of Neu5Gc, such as mouse-derived NS0 cells. We propose an alternate 
method to remove Neu5Gc that employs enzymatic glycan trimming. Four sialylated 
glycoproteins, including the FDA approved glycoprotein therapeutic, erythropoietin, 
were treated with a sialidase to trim off all sialylated glycans, including Neu5Gc. 
Glycopeptide analysis using mass spectrometry verified sialic acid removal. Both the 
native and modified proteins were also subjected to thermal stress studies, to determine 
melt temperatures, Tm, using far UV circular dichroism. The desialylated glycoproteins 
had higher Tm values, compared to the native (sialylated) proteins, for all four proteins 
studied. The Tm data indicates that the method of enzymatic glycan trimming can be 
implemented into glycoprotein production work-flows, without harming protein thermal 
stability. Additionally, glycan trimming could be used on therapeutic glycoproteins to 
prevent adverse immunogenic responses induced by Neu5Gc exposure.  
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4.1 INTRODUCTION 
Pharmacological properties of therapeutic glycoproteins are heavily influenced by 
post-translational modifications (PTMs) such as N-linked glycosylation.1-3 Complex type 
N-linked glycans that terminate in sialic acid residues have shown to be crucial to the 
efficacy of some therapeutic products, such as recombinant human erythropoietin 
(rhEPO).4 Erythropoietin, used for treating anemia, is also an endogenous protein in 
human serum that circulates to the bone marrow, where it is necessary for erythrocyte 
progenitor cells to differentiate for the production of erythrocytes.5 rhEPO exhibits 
complex behavior in relation to sialic acid residues, in that removal of these terminal 
residues from the N-linked glycans will produce an increased binding affinity for the 
EPO receptor found on the erythrocyte progenitor cells.6-8 Yet, without sialic acid , the 
exposed galactose residues remaining on the N-linked glycans are bound by the liver’s 
galactose binding protein, rhEPO is quickly cleared from circulation, and has no in vivo 
activity.9-12 Sialic acid residues are thus an important part of therapeutic glycoprotein 
composition. 
More than one sialic acid structure is known to exist in non-human mammalian 
cells. The most common form of sialic acid, N-Acetylneuraminic acid (Neu5Ac), is 
added to the terminal positions on complex type N-linked glycans by the glycan 
processing enzymes within Golgi of the expression hosts.13,14 A sialic acid derivative, N-
Glycolylneuraminic acid (Neu5Gc), can also be added to the glycans. Neu5Gc differs in 
structure from Neu5Ac by just a single hydroxyl group, and is immunogenic to 
humans.15 Neu5Gc is not found in healthy human adults,16 and its introduction into the 
human body can instigate an immune response where antibodies against complex N-
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linked glycan epitopes are produced.17 More than one neutralizing antibody has been 
reported against Neu5Gc, including the anti-Paul-Bunnell antibody and the anti-
Hanganutziu-Deicher antibody.18-19 Some patients receiving rhEPO therapy for anemia 
have developed such a severe immune response to conformational epitopes of rhEPO 
complex glycans, their anemia worsened severely and they became dependent upon 
higher risk treatments, including blood transfusions.20-23  
Optimizing the N-linked glycans of therapeutic glycoproteins is, therefore, an 
important part of preventing adverse responses to this entire class of therapeutics. The 
amount of Neu5Gc varies by expression host cell line, accounting for up to 50% of sialic 
acid species in mouse derived NS0 cells, and 7-15% of sialic acid in Chinese hamster 
ovary (CHO) cell lines.24-25 Due to requirements such as sialylation, the majority of 
currently approved glycoprotein therapeutics are produced in CHO cells and not in the 
mouse derived NS0.26 Efforts in preventing Neu5Gc being added to therapeutic 
glycoproteins rely on a method using anti-sense RNA technology to reduce production 
of the sialic acid derivative, but only a reduction in Neu5Gc content has been reported.27 
To ensure the safety of glycoprotein therapeutic products, alternate methods are 
needed. 
A method for removing specific glycans from existing N-linked glycan structures 
in glycoproteins has been demonstrated recently; the method (glycan trimming) cleaved 
mannose monosaccharides from a glycoprotein, without altering the protein’s structure 
or function.28 If this method were also applicable to the removal of Neu5Gc from 
glycoproteins, this approach could open up a new pathway for producing therapeutic 
glycoproteins with reduced immunogenicity.  
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To investigate this application of glycan trimming, recombinant human 
erythropoietin (rhEPO) was expressed in CHO cells, purified using lectin affinity, and 
then subjected to trimming using Sialidase A, to remove all the sialic acid residues. The 
success of the trimming reaction was verified by mass spectrometry. Both native and 
enzymatically modified proteins were subjected to thermal stress while using circular 
dichroism (CD) to monitor the loss of secondary structure. A diagram of the work-flow is 
provided in Scheme 1. After promising results with rhEPO were obtained, the glycan 
trimming method was also applied to three commercially available sialylated 
glycoproteins, to determine the generality of the method. This is the first study to 
demonstrate that glycoprotein therapeutic products do not lose their thermal stability 
when glycan trimming methods are used to remove sialic acid residues, and this 
approach offers a strategy for completely removing immunogenic glycan structures on 
therapeutic glycoproteins. 
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Scheme 1.  Experimental work-flow for removing sialic acid residues from the N-linked glycans of 
therapeutic glycoproteins and the characterization methods that follow glycan optimization. Symbols: □ N-
Acetylglucosamine, ● galactose, ○ mannose,  N-Acetylneuraminic acid,  N-Glycolylneuraminic acid. 
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4.2 EXPERIMENTAL PROCEDURES 
 
4.2.1 Materials 
The CHO-K1 cells were a gift from Dr. Jeff Krise (University of Kansas, 
Department of Pharmaceutical Chemistry, Lawrence, KS). Water was purified using the 
Millipore Direct Q-3 system (Millipore, Billerica, MA). All other materials were obtained 
from Sigma Aldrich (St. Louis, MO) unless otherwise specified. All solutions were 
passed through a 0.2 µm filter prior to use.  
 
4.2.2 Cloning and Construction of the Expression Vector for rhEPO 
 The cDNA of human erythropoietin (hEPO) was obtained from ATCC 
(NM_000799) (Manassas, VA). The hEPO gene was amplified from this template in a 
thermocycler using the following primers: 5’- GGACTTTCCAAAATGTCG -3’ (forward 
primer) and 5’-
CGCGCGTCTAGATCAGTGGTGGTGGTGTCTGTCCCCTGTCATGCAGGC-3’ (reverse 
primer with XbaI restriction site and His4-tag), (Integrated DNA Technologies, Inc., 
Coralville, IA). Due to the lack of a compatible restriction site in hEPO, the forward 
primer corresponds to an upstream sequence embedded in the template plasmid. Use 
of the upstream sequence permits inclusion of a close, in-frame EcoR1 site for use in 
subcloning of the amplified gene product. Four histidine residues were added to the C-
terminal end of the sequence, preceding the stop codon, as an affinity tag for use with 
IMAC purification. The amplified insert and the pCMV6-XL5 vector (Origene 
Technologies Inc., Rockville, MD) were digested with the corresponding EcoRI and XbaI 
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endonucleases. Each DNA reaction was separated, visualized with ethidium bromide 
and purified from agarose gels, and the insert and vector were ligated together by 
overnight incubation with T4 Ligase (Promega, Madison, WI) at 16 °C. The ligation 
reaction was then transformed into competent BL21(DE3) E. coli (Novagen, Gibbstown, 
NJ) using a standard heat shock protocol. Transformed colonies were obtained by 
overnight growth at 37 °C on selective LB agar plates containing 100 µg/mL ampicillin. 
Individual colonies were selected and used to inoculate 10 mL Luria Broth (LB) 
containing 100 µg/mL ampicillin. Liquid cultures were grown overnight in an incubating 
shaker at 37 °C. Plasmid DNA was isolated from each of the overnight cultures using 
the QIAprep Spin Miniprep Kit (QIAGEN, Valencia, CA). The isolated DNA samples 
were quantified using UV absorbance at 260 and examined for purity using 260/280 nm. 
Constructs were checked for the incorporation of an insert of the correct size; each was 
incubated with the aforementioned nucleases and separated using agarose gel 
electrophoresis. DNA constructs were verified to be correct by bidirectional sequencing 
(Northwoods DNA Inc., Bemidji, MN) using the forward (5'-GGACTTTCCAAAATGTCG-
3') and reverse (5’-ATTAGGACAAGGCTGGTGGG-3’) primers included with the pCMV6 
vector from Origene Technologies Inc. 
 
4.2.3 Cell Culture and Transfection 
CHO-K1 cells were seeded and maintained using complete high glucose 
Dulbecco’s Modified Eagle Medium (DMEM) (Thermo Scientific Hyclone, Logan, UT). 
To the medium, supplemental MEM Non-Essential Amino acids 100x (ATCC, 
Manassas, VA), 10% fetal bovine serum (Mediatech, Inc. Manassas, VA), 100X 
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penicillin/streptomycin (ATCC, Manassas, VA), and 150 mM L-Proline were added. 
Cells were maintained in T-75 flasks (BD, Franklin Lakes, NJ) with 24 mL of medium 
and kept at 37 °C and 5% CO2. Passage was performed using two wash steps with pre-
warmed phosphate buffered saline (10 % PBS) alone and then PBS containing trypsin 
(0.25% trypsin with 0.1% EDTA) to remove the adherent cells from the surface of the 
flask. After three to five minutes, the suspension was centrifuged at 3800 x g for 2 
minutes in a 15 mL tube, the supernatant was removed via vacuum, and the cells were 
resuspended via gentle pipetting into 6 mL of the culture medium described above, then 
reseeded.  
Cells were allowed to grow to 50% confluency and then transfection was 
performed with 4 µg of hEPO DNA and 20 µL of Turbofectin 8.0 transfection reagent 
(OriGene Technologies, Inc., Rockville, MD) per T-75 flask. The supernatant was 
decanted after 24 hours and the medium replaced. After an additional 24 hours, the 
supernatant was collected and concentrated to 0.5 mL using centrifugal filtration 
devices (Millipore, Billerica, MA) with a 10 kDa molecular weight cut off (MWCO) at 
9000 x g. 
 
4.2.4 Lectin Affinity Chromatography (LAC) Purification 
A cartridge (5-mL) containing Maackia amurensis leukoagglutinin (MAL) lectin 
resin (Qiagen, Valencia, CA) was equilibrated according to the manufacturer’s 
directions using the indicated binding/wash buffer. The concentrated supernatant (0.5 
mL) containing the rhEPO glycoprotein, from a single supernatant collection, was mixed 
with an equal volume of binding/wash buffer and loaded onto the column at 1 
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mL/minute. The column was washed using 50 mL of binding/wash buffer at 4 mL/min, 
and the rhEPO was eluted into 50 mL of elution buffer containing 200 mM lactose. The 
elution fraction was concentrated to approximately 1 mL as described above. The 
rhEPO protein content was quantified using a standard Bradford assay.  
 
4.2.5 SDS-PAGE Analysis 
 SDS-PAGE 4-12 % Bis-TRIS Midi gels (Invitrogen, Carlsbad, CA) were used for 
electrophoretic analysis. The rhEPO protein sample was concentrated to approximately 
10 mg/mL using a molecular weight cut off filter, mixed with 2X reducing Laemmli 
loading buffer, and boiled for 10 minutes. The samples were loaded, and 
electrophoresis was performed in MES buffer (Invitrogen) per manufacturer’s directions. 
Precision Plus Protein Dual Color stained protein ladder (Bio-Rad, Hercules, CA) was 
utilized in a separate lane for molecular weight approximation. Gels were stained using 
Coomassie (R-250) in excess, overnight. Destaining was accomplished with 20% acetic 
acid in 50/50 methanol/H2O until background was clear.  
 
4.2.6 Enzymatic Glycan Trimming  
 Approximately 300 µg of each commercially available sialylated glycoprotein, 
human alpha-1-acid glycoprotein (AGP1), human serotransferrin (TF), and ovine follicle 
stimulating hormone (oFSH), were dissolved in 10 mM TRIS-HCl, pH 6.0, to a final 
protein concentration of 2 mg/mL. Four µL of Sialidase A (Prozyme, Hayward, CA) were 
added to the protein solution and then incubated at 37 °C for 48 hours. The 
enzyme:glycoprotein ratio used was 1:1500 (mol/mol) for AGP1 and oFSH, and 1:660 
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for TF. The purified erythropoietin (rhEPO) was treated in the same manner, with a ratio 
of enzyme:glycoprotein at 1:1500 (mol/mol). Sialylated protein samples were made to 
the same protein concentration, and 4 µL of water were added in place of enzyme.  
 
4.2.7 Mass Spectrometric Verification of Glycan Removal 
 Aliquots of glycoprotein samples were exposed to either 4 M or 6 M urea, 
reduced using dithiothreitol (DTT) at 15 mM, and then incubated at 37 °C for one hour. 
Iodoacetamide (IAA) was added for alkylation at 25 mM, and the samples were 
incubated in the dark at room temperature for one hour. DTT was again added to 
neutralize any excess IAA, for a final DTT concentration of 40 mM. Solutions were then 
diluted using 10 mM TRIS-HCl until urea concentration was approximately 1.5 M and 
the pH was adjusted to 7.5. Sequencing grade trypsin (Promega, Madison, WI) was 
added in a 1:30 (wt/wt) enzyme:glycoprotein ratio. Protease digestion was allowed to 
proceed for 18 hours at 37 °C and stopped by adding 1 µL of glacial acetic acid for 
every 100 µL of digested glycoprotein. Samples were stored at -20 °C until analysis.  
 Full mass spectrometric scans (MS1) and tandem mass spectrometry scans 
(MS2) of the peptide/glycopeptide digestion samples were collected by performing 
online high performance liquid chromatography electrospray ionization mass 
spectrometric (HPLC/ESI-MS) analysis using a hybrid, linear ion trap Fourier transform 
ion cyclotron resonance mass spectrometer (LIT-FTICR-MS), (Thermo Fisher Scientific, 
San Jose, CA). Chromatography was controlled using the UltiMate capillary LC system 
(Dionex, Sunnyvale, CA) and FAMOS autosampler. LC mobile phase was (A) 99.9% 
H2O and (B) 99.9% acetonitrile, both with 0.1% formic acid. Flow rate was set to 5 
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µL/min for the capillary column (C18 300 µm i.d. × 100 mm, 300 Å, by Micro-Tech, Vista, 
CA), onto which 5 µL of digested product was loaded. MS1 scans were collected with 
the spray voltage set to 2.8 kV in positive ion mode, ion transfer tube heated to 200 °C, 
and nebulizing gas (N2) at 10 psi. The resolution was set to 100,000 for the ion m/z 400. 
The MS2 data was collected using data dependent mode where the 6 most intense ions 
in the MS1 scans were selected for fragmentation using collision induced dissociation 
(CID). Additional parameters for MS2 experiments included using a 2 Da isolation width, 
activation q = 0.25, and collision energy = 30%, as defined by the Xcalibur software 
(version 2.0, Thermo Fisher Scientific, San Jose, CA). A wash and a blank run were 
included in between each sample analysis. Data were interpreted with the aid of 
GlycoPepDB29 and GlycoPepID30.  
 
4.2.8 Circular Dichroism Studies 
 The commercially available proteins were diluted using 10 mM TRIS-HCl to a 
final concentration of 0.8 or 1.0 mg/mL, and the rhEPO samples were dialyzed using 3 
one L buffer exchanges, into 10 mM TRIS-HCl, final concentration at 0.5 mg/mL as 
determined using a standard Bradford assay. The protein samples were placed in a 
jacketed, quartz, 1.0-mm pathlength sample cell and sealed tightly. Far UV CD 
measurements were made using a Jasco J-715 spectropolarimeter (Tokyo, Japan) with 
an attached circulating water bath that was built in-house. Experiments were performed 
with a sensitivity of 100 mdeg and scan speed of 10 nm/min, under constant nitrogen 
flow. Background solutions contained 4 µL of enzyme for the desialylated (trimmed) 
samples. Thermal unfolding experiments and replicate studies were completed using 
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either the Jasco J-715 spectropolarimeter or a Jasco J-810 spectropolarimeter while 
monitoring changes in ellipticity at 222 nm, in response to increasing temperature (25-
90 °C). Temperature was increased using an attached Peltier temperature controller. 
Scans were collected using a data pitch of 0.2°C, at a rate of 12°C/hour. Scan speed 
was 10 nm/min and a 2 second response time was allowed. The transition temperature 
was calculated using a sigmoidal fit algorithm within Origin (version 6.0), and the 
sialylated and de-sialylated samples were compared for each protein. A total of 5 
separate preparation and analysis experiments were performed for each commercially 
available protein. Three replicates were performed on rhEPO. 
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4.3 RESULTS 
 Some sialic acid derivatives on therapeutic glycoproteins are known to be 
immunogenic to humans.15,17 Enzymatic glycan trimming was employed to remove the 
sialic acids from a therapeutic glycoprotein, recombinant human erythropoietin (rhEPO), 
using a sialidase. Mass spectrometric analysis was used to verify that the glycan 
trimming reaction was successful, then thermal melt studies were performed using far 
UV CD to determine if enzymatic glycan trimming inflicts damage to the thermal stability 
of the therapeutic glycoprotein. The thermal scans indicated the trimmed glycoproteins 
were more stable than the native sample, which was unexpected. Three commercially 
available, sialylated glycoproteins were then studied using the same methods to ensure 
that the improved thermal stability of desialylated glycoproteins was not an unique 
feature to rhEPO.  
 
4.3.1 SDS-PAGE Analysis of Recombinant Human Erythropoietin  
 In Figure 1, the results from SDS-PAGE analysis on the purified and 
concentrated rhEPO glycoprotein are shown. In the lane containing the expressed 
protein, a large, round band appears between the 37 and 50 kDa protein standards, and 
there are no other significant bands present in this concentrated protein sample. The gel 
was over-loaded with protein intentionally, so that any small impurities would also be 
concentrated and detected; however, no other significant bands appeared. This result 
indicates that a purified protein is present. The molecular weight is expected to be 
between 37-40 kDa for the recombinant form of EPO, which is heavily glycosylated and 
sialylated when produced in CHO cells.31 The rhEPO possesses three N-linked glycan 
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sites, and one commonly utilized O-linked glycan, and these heavily branched and 
sialylated glycans contribute to the carbohydrates comprising 40% of the glycoprotein’s 
molecular weight.31,32  
 
 
 
Figure 1. SDS-PAGE analysis of recombinant human erythropoietin at high concentration. No other 
significant bands are present. 
 
4.3.2 Enzymatic Glycan Trimming and Verification  
After purification and dialysis, a portion of the rhEPO sample was treated with a 
commercially available sialidase to remove the sialic acids. To confirm that the sialidase 
catalyzed the removal of sialic acids from the N-linked glycans of rhEPO, mass 
spectrometric analysis of glycopeptides was conducted. To conduct these experiments, 
the glycoproteins were digested using proteomics grade trypsin, which produces a 
mixture of peptides and glycopeptides. Separation of the mixture was achieved by 
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performing online liquid chromatography during LC/ESI-MS analysis. Figure 2a displays 
a full (MS) mass spectrum obtained from analyzing the sialylated form of rhEPO, with a 
peak at m/z 1547.18 in the 4+ charge state, corresponding to the mass of a 
glycopeptide of rhEPO containing one missed cleavage within the peptide portion, and 
three sialic acid residues. The peptide and N-linked glycan composition is shown near 
the peak in Figure 2a. Tandem mass spectrometric experiments were also performed 
on this peak. The product ions provide additional confirmation of the glycan 
composition. In Figure 2b, the detected product ions are shown, the predominant 
fragmentation pattern includes the successive loss of sialic acid residues. This 
fragmentation pattern is typical of multiply charged glycopeptides, as demonstrated 
previously.30,33 
 The desialylated rhEPO sample was analyzed in the same way. In Figure 
2c, a full mass spectrum is shown using the same m/z window as the sialylated sample. 
In this spectrum, no sialylated glycopeptide is detected. We ruled out the possibility of 
this peak being absent because of slight chromatographic drifts in retention time by also 
searching for this peak in the MS data at ± 5 minutes from the retention time of the peak 
in Figure 2A, but even when searching for the sialylated glycopeptide peak with an 
expanded retention time window, the peak at m/z 1547.18 is not observed. Instead, a 
peak at m/z 1328.84 in the 4+ charge state is present, corresponding to the same 
peptide and N-linked glycan, except the sialic acids are no longer present. See Figure 
2d. The modified N-linked glycan composition obtained by using enzymatic glycan 
trimming via sialidase is indicated near the peak in the figure. After confirmation of sialic 
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acid removal, the sialylated and desialylated rhEPO samples were subjected to thermal 
stress and monitoring using circular dichroism (CD). 
 
 
 
Figure 2. Glycopeptide analysis of erythropoietin. (a) Full mass spectrum with a glycopeptide in the 4+ 
charge state. Glycan composition is shown next to the monoisotopic peak, m/z 1547.18. (b) Tandem MS 
(MS/MS) was used to fragment the peak m/z 1547 and fragments produced in the 4+ and the 3+ charge 
states indicate the loss of three sialic acid residues from the N-linked glycan. (c) In the desialylated 
erythropoietin sample, the m/z 1547.18 is no longer present, at the same retention time or ± 5 minutes, 
indicating this sialylated glycopeptide species is no longer present. Instead, a peak at m/z 1328.84 is 
present in the 4+ charge state in spectrum (d), indicating that the glycopeptide is present, except the sialic 
acids have been enzymatically removed. Symbols: □ N-Acetylglucosamine, ● galactose, ○ mannose,  
N-Acetylneuraminic acid. 
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4.3.3 Circular Dichroism Monitoring Loss of Secondary Structure 
 The sialylated and desialylated rhEPO samples were subjected to increasing 
temperature and monitored for the loss of secondary structure using Far UV CD at 222 
nm. In Figure 3a, data is shown for a single preparation of rhEPO, where the data for 
the sialylated form is shown in black, and the desialylated data is shown in gray. The 
desialylated sample is noted to have a higher melt temperature (Tm) than the sialylated 
rhEPO sample, where the transition occurs at a lower temperature. The experiments 
were repeated in triplicate with separate sample preparations, and each time the 
desialylated sample produced the higher Tm value. Average Tm values for the rhEPO 
samples are given in Table 1.  
 
 
 
Figure 3. Temperature dependant loss of secondary structure monitored at 222 nm using Far UV CD, for 
(a) rhEPO, (b) AGP1, (c) TF, (d) oFSH Symbols: ---- sialylated glycoproteins and ----- desialylated 
glycoproteins. 
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 To investigate the general applicability of the observation that enzymatic glycan 
trimming produces more stable proteins, when sialic acids are trimmed from sialylated 
glycoproteins, three commercially available glycoproteins were obtained and subjected 
to the same experiments as the rhEPO samples (enzymatic glycan trimming, followed 
by melt studies using CD). The three glycoproteins were human alpha-1-acid 
glycoprotein (AGP1), human serotransferrin (TF), and ovine follicle stimulating hormone 
(oFSH), and the results for these samples are given in Figure 3b-3d. In Figure 3b, the 
sialylated AGP1 scans produced a lower Tm value than the desialylated samples. 
Experiments were repeated until N=5, and average Tm results are given in Table 1. The 
TF and oFSH results, Figure 3c and 3d respectively, also produced similar results, 
where in each study the transition occurred at the lower temperature for the sialylated 
samples. 
 
Table 1. Tm values for each of the four sialylated glycoproteins, before and after enzymatic glycan 
trimming. N = 5 for AGP, TF, and oFSH, where each experiment was performed separately with individual 
sample preparations. N = 3 for rhEPO. 
 
Protein rhEPO AGP1 TF oFSH 
Sialylated Tm (°C) 58 56 61 65 
De-sialylated Tm (°C) 66 61 65 76 
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4.4 DISCUSSION 
 Removal of glycan residues using enzymatic glycan trimming has been 
demonstrated previously for mannose residues.(Toumi) This new study was designed to 
accomplish two goals: use the glycan trimming method to solve a therapeutic 
glycoprotein problem, and quantify any loss of thermal stability the glycoprotein might 
experience because of glycan trimming. The chosen therapeutic glycoprotein was 
recombinant human erythropoietin (rhEPO), which is used to treat anemia. The N-linked 
glycans of rhEPO terminate with sialic acid residues, but some derivatives of the sialic 
acid, especially the Neu5Gc species, are immunogenic to humans and can cause 
adverse responses to treatment.20-23 We propose using enzymatic glycan trimming with 
a sialidase to remove sialic acids as an additional step in the therapeutic glycoprotein 
production work flow, to prevent adverse immunological effects of therapeutic 
glycoprotein administration.  
The rhEPO was expressed in CHO cells, purified using lectin affinity, and then 
treated with a sialidase to remove all the sialic acid residues. The choice of enzyme for 
the glycan trimming work is important, because it is dependant upon the enzyme’s 
specificity for both the targeted glycan’s identity and linkage with other sugars. The 
sialidase chosen for this work, Sialidase A, is known to have broad specificity for sialic 
acid in the main form, Neu5Ac, as well as common derivatives such as Neu5Gc.34 The 
linkage specificity of this glycosidase was also optimal for these experiments. The 
expression host glycosylation machinery determines the linkage of the sialic acid to the 
rest of the glycan, and it has been demonstrated that CHO cells produce sialic acids 
with an α-(2,3) linkage to the corresponding galactose residue, and not an α-(2,6), 
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which is more common in humans.4,25,31 The linkage specificity for the activity of the 
chosen sialidase is known to be approximately the same for α-(2,3) and α-(2,6) linkages 
between sialic acids and galactose,34 making Sialidase A useful choice for this study.  
 This study focused on enzymatic removal of sialic acid residues for use in 
optimizing glycans on therapeutic glycoproteins, and investigating what effects sialic 
acid removal may impart on glycoprotein stability. The rhEPO, with and without sialic 
acid, was subjected to thermal stress and monitored for loss of secondary structure 
using Far UV CD. Since sialic acids have been demonstrated to be very important to 
rhEPO in vivo activity,9-12 it was predicted that removal of sialic acid could negatively 
impact the glycoprotein’s thermal stability. Instead, the desialylated samples of rhEPO 
were observed to have a higher melt temperature (Tm) value than the unmodified 
glycoprotein. To determine if this was a property unique to rhEPO, three commercially 
available sialylated glycoproteins were obtained and subjected to the same 
experimental methods. In each case, the Tm values indicated that the sialic acid 
trimming method did not harm the thermal stability of the glycoproteins, but instead 
improved it. These results indicate that the trimming method can be implemented into 
therapeutic glycoprotein production methods without harming protein stability.  
 The study described above was designed to solve the known immunogenicity 
problems with sialic acid derivatives (such as Neu5Gc) present on therapeutic 
glycoproteins. Removal of Neu5Gc will improve immunogenicity profiles, but therapeutic 
products such as rhEPO do not exert a therapeutic effect without some form of sialic 
acid.9-12 Methods to add the desired sialic acid onto N-linked glycan structures using 
glycosyltransferases have been demonstrated by Paulson et al.35 Enzymatic glycan 
 102 
trimming of sialic acid could be used in conjunction with the glycosyltransferase method 
to produce therapeutic glycoproteins with desirable sialic acid content. Another potential 
application for sialic acid glycan trimming could be to remove the α-(2,3) linked sialic 
acids found on N-linked glycans produced in CHO cells, in conjunction with 
glycosyltransferase methods to add only α-(2,6) linked sialic acids to IgG used to treat 
autoimmune disorders, as the α-(2,6) configuration of sialic acid on IVIG has been 
identified as responsible for anti-inflammatory properties.36 Improving the functional 
activity of a therapeutic glycoprotein such as IVIG could lead to lower doses and less 
frequent administration.36  
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4.5 CONCLUDING REMARKS 
 To demonstrate the practicality of using enzymatic glycan trimming to remove 
sialic acids from therapeutic glycoprotein, rhEPO was generated and treated with a 
sialidase. During study of the glycoprotein thermal stability, unexpected results were 
observed, where the desialylated samples produced a higher melt temperature (Tm) 
than the sialylated form. To determine if this was a property unique to only one protein, 
three other sialylated glycoproteins were treated with a sialidase, and analyzed. The Tm 
values in all cases indicated that the sialic acid trimming method does not negatively 
impact the stability of the glycoprotein; in fact it improves the stability. These results 
indicate that the sialic acid glycan trimming method can be implemented without 
damaging the thermal stability of glycoprotein therapeutics such as rhEPO. Use of this 
method to remove immunogenic sugars will reduce the likelihood of adverse 
immunogenic responses to glycoprotein therapeutic treatments.  
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CHAPTER 5 
ENHANCING HUMAN GROWTH HORMONE STABILITY USING 
DESIGNER GLYCOSYLATION 
 Degradation pathways, such as asparagine deamidation, negatively impact the 
stability of therapeutic proteins like recombinant human growth hormone (rhGH), 
leading to decreases in efficacy, safety, and functionality. We have developed a novel 
approach to limiting protein deamidation by introducing a nonnative N-linked 
glycosylation site at asparagine residues that are known to readily deamidate. The sites 
are glycosylated by a eukaryotic expression host, and the glycan is enzymatically 
trimmed in vitro to contain a single monosaccharide residue. This moiety is designed to 
sterically hinder deamidation. To demonstrate this technology, three mutant, 
glycosylated rhGH proteins were produced. Circular dichroism (CD) was used to study 
secondary structure, and the proteins were found to possess a higher degree of alpha 
helical character after glycan trimming. The proteins’ stability was also assessed by 
studying loss of secondary structure, under conditions that promote asparagine 
deamidation (using far UV CD). The superior stability of the glycosylated proteins was 
demonstrated by comparing melt temperature (Tm) values for the three rhGH mutants to 
Tm values obtained using a nonglycosylated growth hormone standard. Using this 
glycosylation engineering strategy to improve protein stability will lead to better 
therapeutic protein products. 
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5.1 INTRODUCTION 
 Recombinant DNA technology has become a vital tool for the pharmaceutical 
industry, allowing for mass production of therapeutic hormones and other proteins.1 
Despite impressive progress in biopharmaceutical formulation methods, some proteins 
continue to suffer from common degradation pathways, such as deamidation.2,3 
Recombinant human growth hormone (rhGH) is a prime example.4  
 Human growth hormone (hGH) is an endogenous protein required for proper 
growth.5 Growth hormone deficiencies were previously treated using growth hormone 
extracted and purified from the pituitary glands of human cadavers.6 The yield of hGH 
obtained from this source was insufficient to meet rising demand, while the extraction 
techniques used were overly complex.6,7 This problem has been partly solved by 
treating growth hormone deficiencies with recombinant human growth hormone 
(rhGH).8-10 Although administration of rhGH has proven beneficial, the protein is 
susceptible to chemical degradation (via deamidation in particular), and the recombinant 
protein is not stable.4 As a result, the shelf life and circulation half-life of the medication 
is limited, and daily injections are required.11 Optimizing the stability of proteins such as 
rhGH would be advantageous for more efficient drug storage, dosing schedules, and 
patient benefit. To accomplish the goal of improving the stability of rhGH, we designed a 
strategy to prevent the most common degradation pathway for this protein, deamidation. 
 Nonenzymatic deamidation is the primary means by which rhGH degrades, most 
often occurring at N149 and N152.12-14 (Amino acid positions are described according to 
accession number P01241, www.uniprot.org.) Deamidation can be an important 
component in regulating biological systems, by acting as a “molecular clock”.15 In the 
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clinical setting, deamidation of therapeutic proteins has a negative affect on higher order 
structure that results in a decrease in the drug’s activity, half-life in vivo, as well as shelf 
life.4,12-14,16-19 When susceptible asparagines (N) deamidate, the amino acid is converted 
into aspartic acid (D).20,21 The N to D shift is accompanied by the replacement of an NH2 
group with an OH , which increases the protein’s molecular weight by one Dalton.20 This 
modification causes further rearrangements in the protein, with the most destructive 
change, in terms of its effect on the protein structure and function, being the addition of 
an extra carbon to the peptide backbone of the protein.20,21 Deamidation is associated 
with reduced rhGH stability and function2,4,14 and induces protein aggregation, further 
hampering the pharmaceutical efficacy of rhGH.22,23  
 Previous efforts to block deamidation-based damage to proteins have focused on 
the chemical residues where the change occurs – asparagines. Chen, et al., replaced 
vulnerable asparagine residues of glucoamylase, from Aspergillus awamori, using site 
directed mutagenesis.24 Results were mixed, where enzyme secretion, thermal stability, 
and activity were impacted depending on the N residue position being mutated, and 
whether the introduced amino acid was Q or D.24  
 Instead of removing asparagine residues at these locations in rhGH, we sought 
to block or slow deamidation by adding an asparagine linked (N-linked) glycan to the 
vulnerable asparagine residues. Asparagine deamidation occurs through a cyclic imide 
intermediate, and demaidation can only occur if the amide nitrogen is not sterically 
constrained.21,25 Therefore, it should be possible to prevent deamidation by adding a 
bulky group to the asparagine residue that will sterically hinder the formation of the 
intermediate species.  
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Incorporation of a glycan at the vulnerable asparagines was accomplished using site-
directed mutagenesis to introduce the N-linked glycosylation consensus sequence, N-X-
S/T, where X is any amino acid other than proline. The consensus sequence was 
attained by mutating the residues after the asparagine. The workflow is depicted in 
Scheme 1. The mutant proteins were expressed in Chinese Hamster Ovary (CHO-K1) 
cells that are known to recognize the N-linked consensus sequence as a signal to add 
complex glycans to the lengthening polypeptide chain.27 The glycosylated mutant rhGH 
proteins were purified using lectin affinity chromatography and analyzed using SDS-
PAGE. Glycans were trimmed enzymatically using endo-β-N-acetylglucosaminidase F 
(Endo F3), to ensure that a single N-acetylglucosamine was attached to the asparagine 
residue on the rhGH protein. The secondary structure of the resultant mutant proteins 
was studied using circular dichroism (CD), and thermal stability studies were performed 
under conditions that encourage deamidation.  
 112 
Scheme 1. Discouraging deamidation using glycosylation. The amino acids near two asparagine 
residues known to readily deamidate are modified to include N-linked glycosylation sites. N-linked glycans 
are acquired during expression with a eukaryotic host cell line, purified using lectin affinity 
chromatography, and enzymatically trimmed to remove the majority of the glycan mass. The remaining 
monosaccharide residue is intended to sterically block the nonenzymatic deamidation reaction. 
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5.2 EXPERIMENTAL PROCEDURES 
 
5.2.1 Materials 
 The CHO-K1 cells gift from Dr. Jeff Krise (University of Kansas, Department of 
Pharmaceutical Chemistry, Lawrence, KS). All water was purified using a Millipore 
Direct Q-3 system (Millipore, Billerica, MA). Other materials were obtained from Sigma 
in the highest grade available, unless otherwise specified. All solutions were sterilized 
by filtration prior to use. 
 
5.2.2 Construction of Recombinant Template Plasmid 
 The mammalian vector pCMV6-XL5, which contained the human hGH gene, was 
purchased from Origene Technologies Inc.(number SC-3300088), and used as the 
template for PCR based site-directed mutagenesis. Features of this plasmid include an 
N-terminal peptide secretion signal to enable secretion of the protein into the media, 
and an N-terminal His4-tag to ease purification. To facilitate plasmid production in E. 
coli, the plasmid also contains the ampicillin resistance gene and ColE1 origin of 
replication.  
 Competent XL-1 Blue E. coli cells (Novagen, Gibbstown, NJ) were transformed 
using a standard heat shock procedure, then plated on Luria broth (LB) with 2% agar 
plates containing 100 mg/mL ampicillin. A colony was selected and used to inoculate 10 
mL of selective LB medium. The resultant DNA was purified using the QIAprep Spin 
Miniprep Kit (QIAGEN, Valencia, CA) and quantified using the Nanodrop® ND-1000 
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Spectrophotometer (Thermo Scientific, Wilmington, DE) according to the manufacturer’s 
instructions.  
 
5.2.3 Site-Directed Mutagenesis of Glycosylation Site 
The vector plasmid was used as a template for amino acid modification to incorporate 
an N-linked glycosylation site at the asparagine residue(s) of interest. Mutagenesis was 
performed using the QuikChange mutagenesis kit (Stratagene, La Jolla, CA) using the 
manufacturer’s instructions. DNA site directed mutagenesis primers (Integrated DNA 
Technologies, Inc., Coralville, IA) were designed to generate the rhGH-H157S mutant: 
(5’ to 3’) c agc aag ttc gac aca aac tca AGc aac gat gac gca cta c (leading) and g tag 
tgc gtc atc gtt gCT tga gtt tgt gtc gaa ctt gct g (reverse), where the mutated bases are 
indicated using capital letters. The rhGH-D160S mutant was generated with primers (5’ 
to 3’) c agc aag ttc gac aca aac tca gac aac gat AGc gca cta c (leading) and g tag tgc gtc 
atc gtt gCT tga gtt tgt gtc gaa ctt gct g (reverse), and the rhGH-H157S,D160S mutant was 
generated using (5’ to 3’) c agc aag ttc gac aca aac tca AGc aac gat AGc gca cta c 
(leading) and g tag tgc gCT atc gtt gCT tga gtt tgt gtc gaa ctt gct g (reverse).   
The mutagenesis product was digested with 1 µL of DpnI enzyme (New England 
Biosciences, Ipswich, MA) to selectively destroy the template DNA. The product was 
used to transform competent XL-1 Blue E. coli cells as described above. Transformed 
cells were selected after overnight growth at 37 °C on LB agar containing 100mg/mL 
ampicillin. Plasmids containing the vector containing the recombinant rhGH gene were 
harvested using a QIAprep Spin Miniprep Kit according to manufacturer’s instructions. 
All miniprep DNA was quantified as described above and sequenced by Northwoods 
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DNA Inc., Bemidji, MN. The desired sequences were each verified prior to transfection, 
with DNA sequence results analyzed using the FinchTV application. 
 
5.2.4 Cell Transfection and Culture 
CHO-K1 cells were seeded and maintained using complete high glucose Dulbecco’s 
Modified Eagle Medium (DMEM) (Thermo Scientific Hyclone, Logan, UT). The medium 
was supplemented with MEM Non-Essential Amino acids 100x (ATCC, Manassas, VA), 
10% fetal bovine serum (Mediatech, Inc. Manassas, VA), 100X penicillin/streptomycin 
(ATCC, Manassas, VA), and 150 mM L-Proline.28  
Cells were maintained in T-75 flasks (BD, Franklin Lakes, NJ) with 24 mL of medium 
and kept at 37 °C in the presence of 5% CO2. Passage was accomplished by two wash 
steps using pre-warmed 10% phosphate buffered saline (PBS) whereupon the cells 
were trypsinized for 3 min to remove the adherent cells from the surface of the flask, 
using 0.25% trypsin with 0.1% EDTA. Then, the cells were harvested by centrifugation 
(3800 x g, 2 min); the supernatant was removed by vacuum aspiration, and the cells 
were then gently resuspended in 6 mL of the culture medium, described above.  
Cells were grown to 50% confluency and transfected with 4 µg of mutated DNA and 20 
µL of Turbofectin 8.0 transfection reagent (OriGene Technologies, Inc., Rockville, MD) 
per T-75 flask, per mutant protein, according to Origene’s recommendations. The 
supernatant was removed by decanting and replacing the media every 24 hrs. After 48 
hrs of growth, the supernatant was collected, filtered using a 0.2 µm pore size filter, and 
concentrated to 0.5 mL using cellulose centrifugal filtration devices (Millipore, Billerica, 
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MA) with a 10 kDa molecular weight cut off (MWCO) at 8800 x g in a fixed angle (35°) 
rotor. 
 
5.2.5 Lectin Affinity Chromatography (LAC) Purification 
A cartridge (5-mL) containing Maackia amurensis leukoagglutinin (MAL) lectin resin 
(QIAgen, Valencia, CA) was equilibrated according to the manufacturer’s directions 
using the indicated binding/wash buffer. The concentrated supernatant (0.5 mL) from a 
single supernatant collection was mixed with an equal volume of binding/wash buffer 
and loaded onto the column at 1 mL/minute. The column was washed using 50 mL of 
binding/wash buffer at 4 mL/min, and the rhGH was eluted into 50 mL of elution buffer 
containing 200 mM lactose. The elution fraction was concentrated to approximately 1 
mL as described above. The protein content was quantified using a standard Bradford 
assay. The rhGH protein was dialyzed using Slide-A-Lyzer dialysis cassette with a 10 
kDa MWCO (Pierce, Rockford, IL) into 10 mM sodium citrate and 150 mM sodium 
chloride, pH adjusted to 5.5 with HCl, with 3 (1 L) exchanges. 
 
5.2.6 SDS-PAGE Analysis 
 12% SDS-PAGE TRIS/glycine gels were generated for electrophoretic analysis. 
Protein samples were mixed with 2X reducing Laemmli loading buffer and water (1:3:3) 
and boiled for 15 minutes. The samples were loaded, and electrophoresis was 
performed at 123 V. Precision Plus unstained protein ladder (Bio-Rad, Hercules, CA) 
was utilized in separate lane(s) for molecular weight approximation. Gels were stained 
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using Coomassie (R-250), overnight. Destaining was accomlished with 20% acetic acid 
and 50/50 methanol/H2O until background was clear.  
 
5.2.7 Enzymatic Glycan Trimming 
 Purified, glycosylated rhGH was treated with Endo β-N-acetylglucosaminidase F 
(Endo F3) (CalBioChem, San Diego, CA) by adding enzyme in a 1:16000 
enzyme:protein molar ratio, and incubating for 72 hours at 37 °C.  
 
5.2.8 CD Secondary Structure Estimation 
 The purified protein was diluted to 0.5 mg/mL in 10 mM sodium citrate and 150 
mM sodium chloride and placed in a jacketed, quartz, 1.0-mm pathlength sample cell. 
Far UV CD measurements were made using a Jasco J-715 spectropolarimeter (Tokyo, 
Japan) with an attached circulating water bath that was built in-house. Experiments 
were performed at 10 °C, with a sensitivity of 100 mdeg and scan speed of 10 nm/min. 
The experiments were conducted under constant nitrogen flow. Scans were performed 
from 260 to 180 nm. Multiple spectra were averaged, smoothed and baseline corrected 
by subtracting signal from background solutions prior to analysis. The publicly available 
DICHROWEB server was used, with the CDSSTR algorithm, to calculate the percent 
protein secondary structure. Secondary structure was studied for the fully glycosylated 
and the enzymatically trimmed glycosylated proteins. 
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5.2.9 CD Thermal Stability Quantitation 
 Each rhGH solution was adjusted to pH 8.0 using NaOH, and subjected to 
increasing temperature, from 22-90°C, with a data pitch of 0.2°C, and at a rate of 
12°C/hour. The ellipticity was monitored at 222 nm. The transition temperature was 
calculated using a sigmoidal fit algorithm within Origin (version 6.0), and compared to a 
completely nonglycosylated, native rhGH protein standard. The experiments were 
performed in triplicate. 
 
5.2.10 Human Growth Hormone Standard 
 A rhGH standard protein was produced as described above, but with the 
following modifications. The standard was generated by introducing a single point 
mutation, D136N, into the gene sequence using primers: (5’ to 3’) atg ggg agg ctg gaa 
AAT ggc agc ccc cgg act g (leading) and c agt ccg ggg gct gcc ATT ttc cag cct ccc cat 
(reverse). Protein verification, purification and handling was the same, except the glycan 
was removed completely using PNGase F, added in a enzyme:protein ratio of 1:10800 
(mol/mol). In addition to cleaving the glycan, the enzyme converts the N to a D, which 
restores the native protein sequence. The CD thermal stability experiments on this 
standard were used as a control for comparison to the mutants stabilized with 
glycosylation. 
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5.3 RESULTS 
 
5.3.1 Mutations to Acquire N-linked Glycans 
 Recombinant human growth hormone (rhGH) was modified to include N-linked 
glycan moieties at asparagine residues that are known to deamidate readily. The growth 
hormone sequence is shown in Figure 1. Mutations were completed to attain the N-
linked glycan consensus sequence N-X-S/T, which acts as a signal in eukaryotic cells to 
add a glycan structure to the growing polypeptide chain. Mutant I contains a serine 
residue in place of histidine, and Mutant II contains a serine in place of aspartic acid. 
Both serine residues are necessary to meet the requirements of the consensus 
sequence. In Mutant III, both mutations were performed to obtain two N-linked 
glycosylation sites on the rhGH protein. The mutated DNA was verified by Northwoods 
DNA Inc., Bemidji, MN, prior to transfection in CHO-K1 cells. Media was collected and 
the mutant proteins were purified using lectin affinity chromatography.  
 
 
Figure 1. Protein sequence of recombinant human growth hormone and the three mutant protein 
sequences. Mutant I rhGH-H157S. Mutant II rhGH-D160S. Mutant III rhGH-H157S,D160S. The mutations 
introduce N-linked glycosylation site(s) into the sequence. The resulting glycans’ function is to sterically 
block deamidation of N155 and N157. Amino acid positions are used according to the gene sequence in 
the figure, with M being position 1. 
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5.3.2 SDS-PAGE Analysis 
 The molecular mass of the glycosylated mutant rhGH proteins was estimated by 
SDS-PAGE to be between 20 and 25 kDa; within the range expected for the 
glycosylated form of rhGH. (Figure 2.) Native hGH is known to have a molecular mass 
of 22 kDa.29 The purity of the rhGH produced was qualitatively assessed by SDS-
PAGE, in lanes 1-3 of Figure 2, no other significant bands are present, indicating mutant 
proteins have been produced to sufficient purity for further study. The mutant proteins 
were treated with the Endo F3 enzyme to trim the majority of the glycan from the protein 
and leave only an N-acetylglucosamine carbohydrate residue attached to the 
asparagine. 
 
 
 
Figure 2. Coomassie stained, 12% acrylamide Tris/Glycine SDS-PAGE gel showing the three 
recombinant human growth hormone mutants. Lanes (1) rhGH-H157S,D160S, (2) rhGH-D160S, (3) 
rhGH-H157S. 
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5.3.3 Circular Dichroism 
 The secondary structure of the rhGH mutant proteins I-III was studied after 
purification, and the proteins did not possess secondary structure similar to native hGH, 
which contains a high degree of alpha helical character. In Figure 3, plot a, the far UV 
CD data for one of the purified rhGH-D160S is shown as a quintessential example. The 
mutant proteins all contain a large N-linked glycan that is not native to the protein, which 
clearly causes distortions in the secondary structure. To remedy this problem, an 
enzyme was used to remove the majority of the glycan. After the glycan was trimmed, 
the mutant proteins more closely resembled the nonglycosylated rhGH standard. The 
trimmed sample of rhGH-D160S is shown as plot (b) in Figure 3. Both the overall 
amount of secondary structure is increased, in going from plot a to plot b, and plot b is a 
closer match to the expected data for native growth hormone. 
 
 
Figure 3. Far UV CD secondary structure. The rhGH-D160S protein was studied after purification (a) 
and was found to not resemble the structure of the rhGH standard protein. After glycan trimming to 
remove the majority of the glycans, the rhGH-D160S sample (b) demonstrated an increase in secondary 
structure and was more similar to the rhGH standard protein. 
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 All mutant proteins were subjected to thermal stress and increased pH, which are 
conditions that facilitate asparagine deamidation.30 Loss of secondary structure induced 
by these conditions was monitored at 222 nm using CD (Figure 4). The rhGH standard 
is noted to have a transition that starts earlier than the glycosylated protein, and loses 
considerably more secondary structure as temperatures continued to increase. The melt 
temperature (Tm) was calculated for each scan, and average results are given in Table 
1 below.  
 
 
Figure 4. Secondary structure loss monitored at 222 nm, in mean residue ellipticity, using far UV CD with 
increasing temperature. The rhGH-H157S,D160S after glycan trimming (in black) is compared to the 
nonglycosylated rhGH standard nonglycosylated (in gray).  
 
 
Table 1. Secondary structure loss was monitored at 222 nm using far UV CD to calculate melt 
temperature (Tm) values for each of the three rhGH mutant proteins. Tm values are then compared to a 
nonglycosylated rhGH standard protein. Each value represents an average of three separate 
experiments. The RSD for each measurement is less than 3 %. 
 
Protein rhGH-H157S rhGH-D160S rhGH-H157S,D160S Standard 
Tm (°C) 77.1 72.2 74.9 66.1 
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5.4 DISCUSSION 
 Recombinant human growth hormone (rhGH) is used to treat intrinsic 
deficiencies in growth hormone production, but these therapeutic proteins have been 
shown to suffer from protein instability. The major cause of instability for rhGH is 
thought to be deamidation of asparagine residues, especially at N155 and N157.12 To 
improve the stability of rhGH proteins, a stabilization scheme was designed using non-
native N-linked glycosylation at the vulnerable asparagine residues. The process by 
which the asparagine residues were modified is summarized in Scheme 1. The work-
flow depicts mammalian cell expression hosts, CHO-K1, which are often used to 
incorporate N-linked glycans onto therapeutic proteins.27,31  
 The purpose of the N-linked glycans is to provide steric hindrance to slow or 
completely inhibit the nonenzymatic reaction that occurs to convert asparagine to 
aspartic acid. It has been demonstrated that asparagine deamidation is slowed when 
bulky or large amino acids near the asparagine are present, or when the tertiary 
structure reduces the amount of space surrounding the asparagine residue.21,25,32 Our 
new approach uses non-native glycosylation to provide the steric hindrance required to 
slow or block asparagine deamidation. The large glycan structures acquired in CHO-K1 
expression hosts are considerably larger than amino acids, and far UV secondary 
structure data indicated the glycan negatively impacted the protein structure. To reduce 
the amount of bulk, an enzymatic method of glycan trimming was used.33 The 
secondary structure of the trimmed protein resemebled the structural data from the 
rhGH standard protein. 
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 To determine if this protein stabilization scheme is effective for rhGH, the mutant 
rhGH proteins were subjected to conditions that promote deamidation and their melt 
temperatures were compared to that of a growth hormone standard. Resulting Tm 
values from thermal stability scans indicated that the glycosylated mutant rhGH proteins 
are more thermodynamically stable than the nonglycosylated standard protein. 
Statistical analysis using the Student’s t-test indicated the differences in Tm values 
between each are statistically significant at the 90% confidence interval. These data 
indicate non-native glycosylation may improve the stability of the rhGH proteins by 
blocking asparagine deamidation.  
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5.5 CONCLUDING REMARKS 
 Protein instability induced by asparagine deamidation may be slowed or 
prevented by the inclusion of a bulky functional group at or near the asparagine residue. 
This concept was used to develop a novel protein stabilization scheme where N-linked 
glycosylation sites are mutated into the protein sequence, at the asparagine residue that 
is vulnerable to deamidation. To demonstrate this new approach, recombinant mutant 
human growth hormone proteins were generated with N-linked glycosylation at two such 
asparagine residues. Enzymatically trimming all the glycan except the monosaccharide 
attached to the asparigine reduced structural changes to the protein, yet still provides 
steric hindrance to block deamidation and increase thermostability. Secondary structure 
scans using circular dichroism indicate that the glycosylated mutants are more 
thermodynamically stable than a non-glycosylated growth hormone control. The method 
of including an N-linked glycan at vulnerable asparagine residues is a new approach to 
improving protein stability, and this approach could be used in developing more stable 
therapeutic proteins.  
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5.6 FUTURE WORK 
 The human growth hormone protein mutants described in this chapter will be 
subjected to proteolytic digestion and high resolution mass spectrometric analysis. 
These studies will provide ancillary support that we have purified the protein of interest, 
and that enzymatic modification of the large N-linked glycan has been achieved. The 
sample preparative steps will employ glycopeptide and peptide analysis, as described in 
Chapter 1, section 1.2.3.1. 
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CHAPTER 6 
 
IMPROVING MASS DEFECT FILTERS FOR HUMAN PROTEINS 
 
 The mass defect of a substance can be used in mass spectral analysis to identify 
peaks as likely belonging to a compound class, such as peptides, if the mass defect is 
within the known range for that compound class. For peptides, a range of possible mass 
defects was calculated previously, using a set of theoretical peptides, where all possible 
amino acid combinations were considered (Mann, M. Abstract from the 43rd Annual 
Conference on Mass Spectrometry and Allied Topics; 1995, ASMS). We compare that 
range of theoretical peptide mass defects to new values obtained from in silico tryptic 
digests of proteins that are abundant in human serum and human seminal fluid. The 
range of mass defect values encompassing 95% of peptides for the human protein data 
sets was found to be up to 50% smaller than the previously reported mass defect range 
for the theoretical peptides. The smaller range established for human tryptic peptides 
can be used to improve peptide mass defect filters by excluding more species that are 
not likely to be peptides, thus improving filter selectivity for peptides during proteomic 
data analysis. 
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6.1 INTRODUCTION 
 Mass spectral data analysis can be a daunting task, but peak identification can 
be enhanced by incorporating mass defect (MD) analysis into the work flow. MD 
analysis is used to predict the elemental composition and the identification of organic 
compounds,1 metabolites,2-4 and petrochemicals,5,6 by using values that are explicit to 
each class of substances. The elemental composition of some peptides can be 
determined using MD calculations, but the utility of the method is generally limited to 
smaller peptides (<800 Da).7 MD analysis is also used to identify and classify multiple 
types of peptide modifications, such as phosphorylation8-10 or cross-linking.11 Peptide 
MD can also be used to deconvolute overlapping peaks,12 support charge state 
determination algorithms,13 and assist in high throughput protein identification, such as 
in peptide mass fingerprinting (PMF) techniques. 
 PMF data analysis can be enhanced by excluding extrinsic peaks from analysis, 
whereas those peaks arise from substances other than the protein(s) of interest.14-15 
Masses are excluded, or filtered, when the MD value is not within the window that is 
characteristic for that analyte. See Figure 1 below for an example of the work-flow. 
 The expected window, or range, of mass defect values for peptides is 
established from theoretical peptide masses. This range is known to encompass only 
selected regions, or “clusters” on the mass scale.16-18 The values in between the 
clusters, referred to as the “forbidden zones”, are where unmodified peptides are not 
found. Any peaks located within these forbidden zones are indicative of peptide 
modifications or non-peptide interferents. Peptide modification can occur with functional 
groups that force the total mass into the forbidden zone, so that the MD is noticeably 
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outside of the anticipated range for peptides, for example with iodine tags,19 or in cases 
of phosphorylation.8-10 PMF experiments benefit from mass defect data filtering, as 
evidenced by higher protein identification probability scores, fewer false positives, and 
increased number of identified peaks.15,20-22 Improvements to peptide MD filters can be 
made, using data sets with actual amino acid usage in place of theoretical peptides, 
because using these data will result in more accurate peptide MD values.18,23 
 
 
Figure 1. Work flow using a data filter that incorporates mass defect data.  
 
 Herein, we calculate mass defect values for two sets of human tryptic peptides 
and compare the data to theoretical peptide MD calculations. The human data sets 
were composed using results from in silico tryptic digestions, which were performed on 
human serum and seminal fluid proteins. Analysis of the human datasets defined the 
range of MD values that encompasses the middle 95% of unmodified peptides. The 
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breadth of this range was compared to that of the range based on theoretical peptide 
calculations. Equations describing the refined MD range are presented for use in PMF 
studies. 
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6.2 EXPERIMENTAL METHODS  
 
6.2.1 Peptide Generation 
 Proteins that are abundant in human serum24 and human seminal fluid 25 were 
chosen for tryptic peptide mass defect analysis. The sequences of the serum and 
seminal fluid protein sets were collected from the UniProt Knowledgebase, using search 
options or published accession numbers, respectively. Sequences containing signal 
peptides and propeptides were truncated so that proteins were analyzed in their 
relevant forms. The sequences were imported into ProteinProspector, version 5.1.8 
Basic, and an in silico digestion was performed using the MS-Digest function. Trypsin 
was chosen for the protease, multiple charges and variable modifications to amino acids 
were omitted, and zero missed cleavages were allowed. Peptides with a minimum of 
five amino acids and within the mass range of 500-8000 Da were chosen for analysis.  
 
6.2.2 Mass Defect Analysis 
 The mass defect was calculated for each tryptic peptide. The mass defect per 
unit mass (MaDPUM) was then calculated by dividing the mass defect by the 
monoisotopic peptide mass, and the values were sorted into 100 Da bins, based on the 
nominal masses of the peptides. The mean and the range of MaDPUM values that 
encompassed the middle 95% of peptides were established for each bin and plotted 
against the peptide mass. The MaDPUM calculations were performed separately for the 
human serum and seminal fluid data sets. A third set of MaDPUM ranges were 
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established for theoretical peptides, based on previously published mass defect data for 
theoretical peptides.16,20  
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6.3 RESULTS AND DISCUSSION 
 Mass defect filters benefit proteomic data analysis by removing non-peptide 
peaks. The removal is performed prior to submitting MS data to an analysis program 
such as MASCOT, and is achieved by eliminating peaks whose numerical mass defect 
values are not within an expected window. Peaks located in the mass ranges outside of 
the expected window, often referred to as the "forbidden zone", are then excluded from 
further analysis.  
 
6.3.1 MaDPUM Calculations 
 In these experiments, we defined the range of mass defect per unit mass 
(MaDPUM) values that incorporates the middle 95% of tryptic peptides from two human 
protein data sets. The sequences of the 50 most abundant seminal fluid proteins25 and 
nearly 300 human serum proteins24 were collected from the UniProt Knowledgebase. 
Each protein was subjected to an in silico tryptic digestion using the MS-Digest function 
within ProteinProspector. The outputs were used to calculate the mass defect (MD) for 
each peptide (equation I), which is defined as the difference between the nominal (NM) 
and monoisotopic masses (MI).1 Nominal mass is an integer sum consisting of the 
integer masses of the most abundant isotopes for each element, e.g. C = 12, H = 1, and 
O = 16.26 The monoisotopic mass is a sum of the exact masses of the most abundant 
isotope for each element in the sample of a substance, e.g. C = 12.0000, H = 1.0078, O 
= 15.9949.26 The MaDPUM was calculated by dividing the mass defect by the 
monoisotopic mass of the peptide, as in equation II. 
(I)  NMMIMD −=  
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(II)  
MI
MDMaDPUM =  
 
6.3.2 Determination of Mean 
 The peptides within the human serum data set were grouped into 100 Da bins for 
analysis, according to the original nominal mass of the peptide. Within each 100 Da bin, 
the mean MaDPUM value was calculated. The global mean was then calculated and 
determined to be 0.00050 for the serum data set. In Figure 2a, the MaDPUM mean 
values are plotted for each nominal mass 100 Da bin for serum peptides. The mean 
MaDPUM value of 0.00050 is higher than the literature value of 0.00048,16,20 which 
incorporates theoretical peptide compositions.  
 Since analysis of the human serum tryptic peptides produced results that differ 
from the literature values, the set of human seminal fluid peptides was analyzed as a 
second data set, to validate that the observations were not characteristic of human 
serum peptides alone. This data is shown in Figure 2b. The seminal fluid data set also 
showed that the global mean value was 0.00050, the same as the human serum data 
set. The agreement in these two data sets suggests that this mean mass defect value 
(0.00050) is appropriate to use for any large set of human proteins.  
 In Figure 2, the smallest peptides are noted to have a mean MaDPUM value 
greater than the average due to a mathematical bias that is based on protease 
specificity.27 All tryptic peptides, except possibly the C-terminal peptide, possess an R 
or K residue at the peptide’s C-terminus.28 The MaDPUM for both R and K is greater 
than the average MaDPUM for all common amino acids, thus creating a slight bias for 
an increased MaDPUM for the small tryptic peptides. 
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Figure 2. MaDPUM mean values as calculated for each nominal peptide mass 100 Da bin. Global mean 
for both (a) human serum peptides and (b) human seminal fluid peptides was determined at 0.00050, 
indicated by the dark, horizontal line. 
 
 
 To understand why global mean values for both the serum and seminal fluid data 
was larger than anticipated (0.00050 instead of 0.00048), the peptide compositions, 
including amino acid usage, were analyzed in the seminal fluid data. In Figure 3a, the 
amino acid usage is shown for the theoretical peptide data set, where the 20 common 
amino acids are utilized equally and would account for 5% of each peptide.  
 
 139 
 
 
Figure 3. Amino acid usage for the 20 common amino acids. The MaDPUM value for each amino 
acid is indicated by bar height in ppm. In (a), the usage is shown for the theoretical protein data set. Each 
amino acid accounts for 5% of utilization. In (b), amino acid usage is shown for the human seminal fluid 
data set. The 20 common amino acids are ranked by increasing usage from left to right. The 5 least 
utilized amino acids, shown in red, possess a MaDPUM value that is less than the average value for all 
amino acids. Amino acid usage in human seminal fluid proteins determines the mean MaDPUM value of 
500 ppm (or 0.00050) 
 
 
 The MaDPUM value for each amino acid is indicated by bar height. In Figure 3b, 
amino acid usage is shown, as calculated for the seminal fluid data set, ranked by 
increasing usage. The ten amino acids to the right, in Figure 3b, would be expected to 
comprise 50.0% of polypeptide compositions if each amino acid were used equally, but 
instead they account for 65.8% of amino acid usage in the seminal fluid data. The five 
least utilized amino acids, to the left in the figure, have MaDPUM values less than the 
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average for amino acids. These observations demonstrate that amino acid usage will 
determine the MaDPUM value for each peptide, and the differential amino acid 
utilization also forces the global average MaDPUM value to 0.00050, higher than 
previously reported. Amino acid usage may prove an important consideration when 
refining mass defect filters for peptides, as usage varies across species.29  
 
6.3.3 MaDPUM Width for Theoretical Peptides 
 The theoretical peptide masses and corresponding MaDPUM values were 
calculated using relationships based on nominal peptide mass, as described 
previously.16,20  
(III)  NMNMMI 00048.0+=  
(IV)  NMW 0001.019.0 +=  
The MI (monoisotopic) masses for theoretical peptides were generated using 
equation III, and the width (W) of the range that encompassed 95% of peptides was 
determined using equation IV.16,20 We used these equations to calculate MaDPUM for 
the theoretical peptides, for each 100 Da bin. Results were plotted against nominal 
peptide mass (Figure 4a). These data are used to assess how similar the width is for 
the experimental MaDPUM data. 
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Figure 4a. MaDPUM values in ppm vs. nominal peptide mass in Da. The red area represents the 
values that are excluded from the human serum tryptic peptide dataset, but included in theoretical peptide 
calculations. The area in yellow represents the human serum tryptic peptide MaDPUM values. The 
differences in MaDPUM widths for the nominal masses shown were found to be between 23-50% for the 
analyzed mass range. 
 
Figure 4b. Mass defect vs. nominal peptide mass in Da. The area representing mass defect values 
that encompass 95% of human serum tryptic peptides is yellow, which is a significantly more narrow 
range of mass defect values than those corresponding to the theoretical peptide data set, shaded in red. 
The upper and lower boundaries incorporating 95% of the serum peptides was calculated for each 100 
Da bin and data points are indicated by blue symbols, ▲ upper boundary and ■ lower boundary. Best fit 
lines through the points were added to the data, and the equations can be found in equations V and VI for 
the upper and lower boundaries of the serum peptides.  
 
6.3.4 MaDPUM Width (range) for Human Biofluid Peptides 
 Extensive studies of the width, or the range, of mass defect values for unmodified 
peptides were conducted on both the serum and seminal fluid proteins. These results 
indicated that no differences existed between the two human data sets for the range of 
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MaDPUM values encompassing the middle 95% of peptides. The width (range) 
determination studies below are presented exclusively using the serum peptides, as that 
set has more data points  
 After calculating the mass defect for each serum peptide in each 100 Da bin, we 
measured the mass defect width for the biofluid data, which can be defined as a range 
of MaDPUM values that incorporated 95% of all the human serum peptides, for each 
100 Da bin. This width was calculated at each 100 Da bin by sorting the MaDPUM 
values in ascending order within the bin, and by manually observing the middle 95% of 
values. The yellow area in the center of Figure 4a represents the experimental width. 
The red areas in Figure 4a represent MaDPUM values that are excluded from the 
serum data’s width, but are included in the theoretical width, according to equation IV.  
 In Figure 4b, the data is plotted differently. Here, MD values are plotted vs. 
nominal peptide mass divided into 100 Da bins. The MD widths are shown for the 
theoretical peptides (in red) and the human serum peptides (in the center shown in 
yellow). The theoretical peptide width was established using equation IV. The width for 
the serum peptides was defined using the experimental data to determine data points 
for the upper and lower boundaries containing 95% of peptides within each 100 Da bin. 
In figure 4b, symbols indicate the individual data points for each bin, and linear trend 
lines to fit the data points are shown. Equations that define the upper and lower 
boundary best fit lines are found in equations V and VI below, respectively. 
(V)  066015.000052738.0 += xy  
(VI)  00038210.000042565.0 += xy  
The R2 values for the best fit lines are 0.99921 or greater.  
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6.3.5 Width Analysis 
 The differences in width between the human serum data set and the theoretical 
data were analyzed to determine how significantly this data will affect the size of MD 
mass analysis filters. The MaDPUM width established for theoretical peptide 
compositions are significantly wider than the width in this study on human serum and 
seminal fluid tryptic peptides. For peptides with a mass of 1000 Da, the width of 
MaDPUM values that would include the middle 95% of serum peptides is 42.3% smaller 
than the width established using theoretical peptides. See Table 1.  
 
Table 1. Observed MaDPUM ranges for peptide data sets. Where ws = width of the observed MaDPUM 
range for human serum tryptic peptides, wt = width of the observed MaDPUM range for theoretical 
peptides. The MaDPUM values are presented in ppm.  
 
 
At a mass of 3000 Da, the difference in width is smaller, 25.6%. These 
differences in the calculated size of the “forbidden zone” for mass defect analysis are 
largest where it makes the most impact, on the lower end of the mass scale; a majority 
of tryptic peptides are less than 3000 Da in mass.30 The differences in width indicate 
that a significant number of additional peaks may be excluded from analysis, without 
losing data from unmodified peptides.  
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6.4 CONCLUDING REMARKS 
 To refine peptide mass defect filters, the mass defect and mass defect per unit 
mass (MaDPUM) values were analyzed for two sets of human proteins and compared 
to data from the literature based on theoretical peptide compositions. The global human 
MaDPUM mean value was found to be 0.00050, larger than previously reported, and 
analysis of amino acid usage indicates that organism usage should be considered when 
refining mass defect filters for peptide analysis. The width of MaDPUM values 
encompassing 95% of peptides within the data sets analyzed were found to be up to 
50% smaller than the width previously established using the theoretical peptide data. 
The selectivity of peptide mass defect filters can be improved by using the refined 
equations presented here, describing the upper and lower boundaries of the mass 
defect values for unmodified peptides. Use of these equations would increase the 
number of excluded extraneous (non-peptide or modified peptide) peaks.  
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